eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Neonatology

Maternal Chorioamnionitis

Michael P Sherman, MD, Professor, Department of Pediatrics, Southern Illinois University School of Medicine; Coordinator, Pediatric Residency Education in Neonatal Intensive Care, St John's Children's Hospital; Professor Emeritus, Department of Pediatrics, University of California, Davis School of Medicine
Katsufumi Otsuki, MD, PhD, Associate Professor, Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan

Updated: Jan 20, 2009

Introduction

Background

Maternal fever during labor, and perhaps other signs and symptoms of chorioamnionitis, often results in a call to the family practitioner, pediatrician, or neonatologist related to concern for the neonate. This communication often causes an evaluation to rule out early onset neonatal sepsis.¹  Because of this, 10-20 newborns are evaluated and treated with antibiotics for every infant with proven bacteremia. The reason for this clinical phenomenon is that newborns who develop an early onset sepsis (EOS), now defined as proven life-threatening infection at less than 72 hours of life, have a high mortality rate. A strong association is observed between very preterm infants dying when younger than 24 hours and chorioamnionitis.²

Frequent clinical evaluations of neonates for EOS began in the 1970s, when group B streptococcal (GBS) infections resulted in a neonatal mortality rate approaching 50%.³ Over the past 25 years, because of a heightened awareness of GBS-related infection in neonates, chemoprophylaxis with antibiotics has significantly reduced the risk of GBS disease and its associated morbidity and death.⁴ In the presence of maternal chorioamnionitis, the dilemma for the physician is determining whether the neonate is truly at risk for localized (eg, bacterial pneumonia, meningitis) or systemic (eg, bacteremia) infection.

Early onset bacterial infections in the newborn may occur when the mother has abnormal bacterial colonization of the urogenital tract, an ascending but silent amniotic fluid infection, or symptomatic chorioamnionitis. Thus, the physician cannot assume that maternal signs and symptoms may be used to identify all infected infants.

GBS infections are no longer the predominant cause of early onset neonatal sepsis; gram-negative organisms are now most predominant,⁵ particularly Escherichia coli.⁶  Some reports have not seen an increase in E coli -related EOS during the era of heightened intrapartum antibiotic use.⁷  

Additionally, methicillin-resistant Staphylococcus aureus (MRSA) , already a common cause of nosocomial infection in maternity and neonatal units, looms as a potential cause of EOS.⁸  So far, maternal colonization during pregnancy with MRSA and an increase in neonatal infection caused by this pathogen has not been reported.⁹

For the clinical setting of suspected chorioamnionitis, this article summarizes the history, physical examination, and laboratory findings in both mother and infant to provide appropriate decision-making tools for cost-effective management of the neonate. An entire issue of Clinics in Perinatology was devoted to infectious diseases during pregnancy.¹⁰  Several chapters in that monograph contain information on the pathophysiology of chorioamnionitis and its adverse consequences in the mother, fetus, and newborn. Since 2005, Romero (2007)^11,12 has reviewed how inflammation and infection result in preterm birth, and Reilly and Faye-Petersen have contributed a monograph on chorioamnionitis and funisitis in NeoReviews.¹³

Pathophysiology

Abnormal bacterial colonization of the rectum and anus during pregnancy may create an abnormal vaginal and cervical microbial environment.¹⁴ More than 2 decades ago, rectovaginal colonization with GBS during pregnancy was found to be associated with this GBS infection of the fetus or newborn.³ Studies have demonstrated that other types of bacteria residing in the vagina, cervix, or both ascend through intact or ruptured fetal membranes and initiate amniotic fluid infection.¹⁵

Urinary tract infection during pregnancy can bathe the vagina with bacterial pathogens and is a recognized risk factor for neonatal sepsis. This observation is particularly true for untreated asymptomatic GBS-related bacteriuria.¹⁶  A high maternal body mass index increases the risk of EOS caused by GBS.¹⁷

Bacterial vaginosis has been recognized as an important cause of premature labor, although overt infection of the neonate with microbes causing bacterial vaginosis is uncommon. Screening for and treatment of bacterial vaginosis and other genital infections may prevent preterm birth,¹⁸ although recent Cochrane reviews conflict regarding the effectiveness of therapy.¹⁹

Many interesting associations related to infection and preterm birth have been made; however, the mechanisms of these relationships are not necessarily understood. Although controversy exists about its role, periodontitis has been linked to prematurity, low birth weight, and fetal growth restriction.²⁰  Blood types A and O are also associated with an increased risk for chorioamnionitis.²¹  The same researchers found relationships between alcoholism, prolonged rupture of membranes, and maternal anemia as factors related to preterm birth.²¹  Obesity during pregnancy has been related to chorioamnionitis in several reports.^22,23,17  

In the mid trimester of pregnancy, ultrasonographic evidence of a short cervix may be the only clinical finding in intraamniotic fluid infection.²⁴  Cervical insufficiency, regardless of bacterial culture results in amniotic fluid, is associated with intraamniotic inflammation, preterm birth and other adverse outcomes of pregnancy.²⁵  Related issues to cervical insufficiency are mechanical methods of cervical ripening that are also suspected of increasing maternal and neonatal infections.²⁶  Each of these factors may be associated with altered host defenses that allow ascending infection from the urogenital tract to placental tissues and amniotic fluid.

Frequency

United States

Incidence of maternal chorioamnionitis in the US population cannot be stated with accuracy, but the occurrence declines as pregnancy advances toward term gestation.¹³  The risk of chorioamnionitis increases based on health conditions and behaviors, as outlined in Pathophysiology. Furthermore, factors such as gestational age, economic conditions, and ethnic differences influence the incidence. Histopathology of the placenta suggests inflammation may occur in the normal course of parturition at term gestation, thus complicating the definition of chorioamnionitis. An increase in histopathologic chorioamnionitis is noted in preterm birth compared with delivery of the healthy term infant. Signs of placental inflammation are present in 42% of extremely low birth weight infants.²⁷  Most agree that infection is directly or indirectly associated with 40-60% of all preterm births.²⁸

International

Developed countries (eg, Canada, western European countries, Australia) probably have an incidence equal to, or perhaps even less than, the rate of chorioamnionitis observed in the United States. In underdeveloped countries, premature rupture of membranes has a strong association with chorioamnionitis, and chorioamnionitis in this setting results in preterm birth with a high mortality rate.²⁹  Classic studies by Naeye demonstrated that malnourished pregnant women in Africa had a higher risk of ascending urogenital infection with subsequent amniotic fluid infection.³⁰

The pathophysiology increased the risk of fetal infection and perinatal death. Infection in these malnourished women was attributed to a decrease in host defense factors in amniotic fluid that regularly prevents disease in this liquor.³¹  In developed countries where women receive suboptimal care and have poor nutrition during pregnancy, a higher incidence of infection can be expected because of altered immune defenses.³²

Mortality/Morbidity

Compared with neonatal deaths associated with maternal chorioamnionitis, mortality in mothers of these infants is rare. The same is not true for the neonate. In a study of infants born at 23-32 weeks' gestation with evidence of intrauterine infection and inflammation, the neonatal death rate was 9.9-11.1%.³³  This study is well known because the analysis concluded that administration of corticosteroids did not worsen any neonatal outcome when intrauterine inflammation and infection were present. 

In a debatable publication from the same study, Andrews et al (2008)⁹ concluded that in utero inflammation was not associated with an increased risk of severe adverse neurodevelopmental outcomes at age 6 years. Rather, these preterm infants born at 23-32 weeks' gestation had unfavorable outcomes influenced more by gestational age at birth, neonatal complications, and the IQ of the caregiver in the home after discharge. As is discussed below, other evidence refutes conclusions about chorioamnionitis and neurodevelopmental outcomes made by Andrews et al.⁹

Another major insight is the long-term neurologic outcome of infants born to mothers with chorioamnionitis. Cerebral palsy (CP)³⁴ and cognitive impairment without CP³⁵ have a relationship to the presence of maternal chorioamnionitis. In particular, funisitis and the fetal inflammatory response syndrome are related to white matter brain injury or periventricular leukomalacia that is linked to activation of cytokine networks.³⁶  Interleukin (IL)-1beta, IL-6, IL-8, IL-18, and tumor necrosis factor (TNF)-alpha are among the cytokines identified as agents related to this in utero and fetal pathophysiology.^37,11  When extremely preterm infants have histopathologic evidence of inflammatory and/or infectious lesions and a severe vascular response in the placenta, the risk of CP is increased.³⁸

In addition to activation of inflammation and adverse neurologic outcomes, the risk of long-term pulmonary disease may be heightened.³⁹  Although controversy remains, in utero infections caused by Ureaplasma and Mycoplasma seem associated with chronic lung disease of prematurity.⁴⁰  Congenital pneumonia caused by Ureaplasma and Mycoplasma occurs; however, during mechanical ventilation and oxygen therapy of preterm infants, these microorganisms may also initiate a prolonged cytokine release in the neonatal lung. Antibiotic treatment to reduce the incidence of chronic lung disease of prematurity when the neonatal lung is colonized or infected with Ureaplasma or Mycoplasma has been disappointing. Chorioamnionitis has been linked to EOS, necrotizing enterocolitis, and severe intraventricular hemorrhage in preterm infants⁴¹ and to spontaneous intestinal perforation.⁴²  

Term infants born to mothers with chorioamnionitis have far less chance of dying; however, the long-term morbidity in term infants is still problematic. In a reasonably homogeneous population of near-term and term infants born in the Kaiser Permanente Care Program, Wu and colleagues (2003)⁴³ concluded chorioamnionitis is an independent risk factor for CP. 

In preterm infants with EOS, elevated numbers of nucleated RBCs were related to increased concentrations of IL-6 in cord blood.⁴⁴  Term infants with evidence of placental inflammation also have elevated circulating fetal nucleated RBCs, and this finding can be associated with CP.⁴⁵

Race

In select populations, race may increase the risk of maternal chorioamnionitis and preterm delivery. Studying histologic chorioamnionitis and preterm birth, Holzman and others (2007)⁴⁶ observed evidence of inflammatory pathology in 12% of placentas from white women and women of other race compared with 55% in black women. If one considers race in the context of adverse circumstances (ie, violence, human immunodeficiency virus [HIV]-infection) associated with inadequate care^47,48 or malnutrition during pregnancy,^49,50 then the incidence of placental inflammation is increased.

Sex

Gender plays an important role in neonatal infection.⁵¹ Along infants with a preterm birth at less than 34 weeks' gestation, prolonged rupture of the fetal membranes and male gender was a risk factor for EOS. More recent studies of EOS caused by ampicillin-resistant E coli did not find that male gender was a risk factor.⁶

Age

Advanced maternal age alone, defined as older than 35 years, has not been identified as a risk factor for chorioamnionitis. However, teenage pregnancy increases the risk of chorioamnionitis. Risks factors associated with teenage pregnancy and chorioamnionitis include smoking, alcohol use, anemia, unemployment, urinary tract infection, and bacterial vaginosis.^52,53,54,55

Clinical

History

• The time-honored clinical signs and symptoms of chorioamnionitis include the following:
  • Fever (an intrapartum temperature >100.4 º F or >37.8 º C)
  • Significant maternal tachycardia (>120 beats per minute [bpm])
  • Fetal tachycardia (>160-180 bpm)
  • Purulent or foul-smelling amniotic fluid or vaginal discharge
  • Uterine tenderness
  • Maternal leukocytosis (total blood leukocyte count >15,000-18,000 cells/μL)
• Of these criteria, intrapartum maternal fever appears to be the most frequent.⁵⁶  Other findings, such as fetal tachycardia, may be less important in the absence of maternal fever.
• When at least 2 of the aforementioned criteria are present, the risk of neonatal sepsis is increased. Clinical signs and symptoms of chorioamnionitis, however, have low predictive value by themselves. Moreover, silent chorioamnionitis is prominent,⁵⁷ and thus signs and symptoms in the infected newborn infant take on added significance.
• An increasing total leukocyte count may be more important than a single determination. Abnormalities in either umbilical vein interleukin (IL)-6 levels or an increasing neonatal immature-to-total neutrophil ratio, along with clinical criteria for chorioamnionitis, improve the sensitivity and predictive accuracy of identifying the septic neonate.
• Risk of neonatal infection increases as the duration of ruptured membranes lengthens.⁵⁸ Chorioamnionitis may initiate uteroplacental bleeding or a placental abruption.⁵⁹ Labor and delivery may be rapid in the presence of chorioamnionitis. Alternatively, infection may cause uterine atony, requiring labor to be augmented with oxytocin. Ultimately, a poor labor pattern may require an instrumented delivery or a cesarean delivery. Each of these antepartum and intrapartum factors must be considered when evaluating the newborn for the presence of bacterial infection.

Physical

The physical examination of the pregnant women with chorioamnionitis may reveal no signs or symptoms of infection.⁵⁷ Conversely, a pregnant woman with chorioamnionitis may appear ill, even toxic.

• Physical symptoms may include the following:
  • Fever
  • Tachycardia (>120 bpm)
  • Hypotension
  • Diaphoresis
  • Cool or clammy skin
  • Uterine tenderness
  • Foul-smelling or abnormal vaginal discharge
• The fetus may also have tachycardia (>160-180 bpm). A biophysical profile (BPP) performed on the fetus using ultrasonography may reveal a lower than normal score, but ultrasonic biophysical profile assessment has not been predictive of clinical chorioamnionitis.⁶⁰  Lack of fetal breathing has been associated with fetal infection.^61,62 Recently, intrauterine ultrasonography has identified "sludge" at the amniotic fluid interface with the cervix that is also associated with hyperechogenic, free-floating material in the amniotic fluid.⁶³  This finding was seen in asymptomatic women at risk for preterm delivery. Aseptic aspiration of the "sludge" showed the material had a low glucose content, many neutrophils, and gram-positive cocci. Furthermore, electronic fetal monitoring lacks precision to identify the fetal inflammatory response syndrome and subsequent neonatal sepsis.⁶⁴  
• Conditions falsely simulating chorioamnionitis include the following:
  • Clinical signs and symptoms of chorioamnionitis are not always associated with placental evidence of inflammation. This is particularly true if maternal fever is the sole criterion for the diagnosis.
    • Epidural anesthesia during the intrapartum period has been associated with fever in the mother and the neonate;^65,66 however, the pathophysiology of the fever and its adverse effects on the mother, fetus, or infant remains controversial.^67,68,69,70
    • Epidural anesthesia and maternal and/or neonatal fevers result in more evaluations for sepsis and antibiotic treatment in neonates, although the incidence of sepsis compared with that in a neonatal population whose mothers did not receive epidural anesthesia during labor is unknown. Epidural anesthesia during labor is associated with other types of neonatal morbidity that are also risk factors for sepsis.
    • Although the exact mechanisms for this phenomenon remain unclear, nulliparity, dysfunctional labor, prolonged labor, maternal exhaustion, dehydration, and/or prolonged rupture of membranes may result in maternal fever associated with epidural anesthesia.
  • In the setting of epidural anesthesia during labor, the following clinical course has been observed. The fetus usually has tachycardia when the mother is febrile during labor. At birth, the newborn may also have a fever (temperature >37.8 º C). If the neonate is not septic, the temperature elevation dissipates rapidly following birth, and the newborn subsequently exhibits normal behavior. Furthermore, these noninfected, febrile neonates have normal Apgar scores and appear remarkably well following birth. Such newborns can be observed for illness rather than undergoing a septic workup and antibiotic therapy. However, judgment must be based on many factors, including the intrapartum administration of broad-spectrum antibiotics to the mother.
• Maternal chorioamnionitis increases the potential that the following clinical presentations may be evident in the neonate. Signs and symptoms of neonatal sepsis are often nonspecific and subtle. The neonate may demonstrate behavioral abnormalities such as lethargy, hypotonia, weak cry, and poor suck. Specific organ involvement may manifest as follows:
  • Tachypnea, respiratory distress (eg, expiratory grunt, retractions), cyanosis, pulmonary hemorrhage, and/or apnea (ie, pulmonary manifestations of pneumonia, sepsis, or both), must be immediately appreciated by caregivers. Nursery personnel must be aware that a neonate who is born without respiratory distress but who develops signs and symptoms of pulmonary disease in the first hours of life has a heightened risk for infectious pneumonia.
  • Tachycardia, hypotension, prolonged capillary refill time, cool and clammy skin, pale or mottled appearance, oliguria (ie, cardiovascular manifestations of sepsis), or a combination of these may be observed. Caregivers must also consider other explanations for these physical findings, such as developmental defects in the cardiovascular system or inborn errors of metabolism.
  • Abdominal distension, vomiting, diarrhea, bloody stools, or a combination of these may be observed. GI symptoms may be nonspecific in patients with early-onset bacterial disease.
  • Thermal regulatory abnormalities (ie, hypothermia or hyperthermia), behavioral abnormalities, apnea, seizures (ie, CNS manifestations), or a combination may be seen. A bulging fontanel or nuchal rigidity is not a reliable sign of meningitis in a neonate.
  • Pallor, petechiae or purpura, and overt bleeding (ie, hematopoietic involvement, liver involvement, or both) may be seen.
• As one physiologic system may affect another, signs and symptoms may originate from more than one dysfunctional organ system. However, many neonatal conditions resemble neonatal sepsis; thus, physician caregivers must have an open mind regarding other clinical conditions that may involve signs and symptoms resembling neonatal sepsis. Those conditions include, but are not limited to, the following:
  • Cardiovascular malformations, especially left-sided obstructive lesions causing poor systemic cardiac output
  • Endocrine disorders that may also cause shocklike states, such as different types of congenital adrenal insufficiency or hypoglycemia associated with hyperinsulinemia
  • Serious CNS trauma or dysfunction from any cause
  • Anemia caused by unrecognized isoimmunization or blood loss from conditions such as fetomaternal transfusion syndrome

Causes

Maternal chorioamnionitis perhaps occurs when protective mechanisms of the urogenital tract and/or uterus fail during pregnancy or when increased numbers of microbial flora or highly pathogenic microorganisms are introduced into the genital environment.^{71,72,73,74,75,76}

• Ascending infection into the vagina, then the cervix, and finally into the uterine cavity, fetal membranes, and placenta is the consequence of many factors (ie, innate host defenses, healthy bacterial flora, bacterial burden, bacterial pathogenetic factors). Recently, a short cervix has been recognized as either a risk factor or a surrogate for microbial invasion of the amniotic fluid.^77,24
• Urogenital hygiene is obviously important in establishing healthy bacterial flora. Healthy bacteria (ie, lactobacilli)⁷⁸ and natural peptide antibiotics in the vagina and cervix may have a role in preventing infections during pregnancy.⁷⁹ Mucus, phagocytes, and natural antibiotic proteins (ie, lactoferrin, lysozyme, beta defensins) in the cervicovaginal secretions attempt to maintain a normal bacterial flora.⁷² Bacterial interference, mainly produced via lactobacilli living in an acid environment and producing bacteriocins, also helps to keep pathogenic bacteria from gaining a foothold in the cervicovaginal secretions.^80,81 These mechanisms of host protection may be altered in a significant number of pregnant women who develop chorioamnionitis.
• Oral hygiene may influence rectal and urogenital bacterial flora during pregnancy. Although the theory is controversial, intense interest has focused on a connection among periodontitis, abnormal rectal colonization, and preterm delivery.^82,83
• Rectal bacterial flora is believed to be important in establishing abnormal urogenital colonization during pregnancy.^84,85,86 Alterations in vaginal and cervical host defense mechanisms during pregnancy cause vaginitis,⁸⁷ bacterial vaginosis, urinary infections, and other urogenital infections. Currently, researchers are trying to understand how host defense mechanisms prevent urogenital infection during pregnancy.
• Orogenital contact may also alter either colonic or urogenital microbial flora and ultimately cause ascending infection and chorioamnionitis.^88,89 Similarly, coitus has been linked with chorioamnionitis.^90,91
• Clinical events associated with chorioamnionitis include the following:
  • History of premature birth (with increasing risk at earlier gestational age)
  • Presence of premature labor
  • Prematurely ruptured fetal membranes
  • Prolonged rupture of the fetal membranes
• In a recent report of patients with clinical signs and symptoms of chorioamnionitis, 38% showed no histologic evidence of placental inflammation. Thus, other causes of signs and symptoms that may resemble maternal chorioamnionitis must be sought.
• Epidural anesthesia during labor may be associated with maternal fever and fetal tachycardia (see Special Concerns). Other conditions, such as dehydration or maternal exhaustion during labor, may result in maternal fever and must be considered as causes of the febrile state.

Differential Diagnoses

Herpes Simplex Virus Infection
Urinary Tract Infection

Other Problems to Be Considered

Urinary tract infections (particularly cystitis)
Vaginitis and cervicitis
Sexually transmitted diseases that cause pelvic infection and inflammation
Viral infections (eg, urogenital disease caused by herpes simplex virus)
Pelvic inflammatory disease
Pelvic adenitis (eg, herpes simplex, enteroviral infections [coxsackievirus])

Workup

Laboratory Studies

• During the intrapartum period, diagnosis of chorioamnionitis is usually based on the clinical criteria. This is particularly true for pregnancies at term.
• Bacteriologic cultures of amniotic fluid and urogenital discharge may be diagnostic for causative pathogens. Investigators have suggested that obtaining cervical cultures is associated with an increased risk of initiating amniotic fluid infection in the presence or absence of ruptured membranes. Silent chorioamnionitis is recognized as an important cause of premature labor.⁵⁷
• The asymptomatic pregnant mother who presents with premature labor or premature rupture of the membranes may require certain studies to exclude silent chorioamnionitis. To diagnose silent or obvious amniotic fluid infection or chorioamnionitis, the physician often uses laboratory examinations of the amniotic fluid, maternal blood, maternal urine, or a combination to make a diagnosis of infection.
• Examination of amniotic fluid and urogenital secretions involves the following:
  • Amniotic fluid, obtained with amniocentesis, may be screened for leukocyte count, Gram stain, pH, glucose concentration, endotoxin, lactoferrin, cytokine levels (eg, interleukin [IL]-6), or a combination of these measured factors.
  • Cytokines commonly quantified in either amniotic fluid or blood include IL-6, tumor necrosis factor-alpha, IL-1, and IL-8.^92,37 No consensus exists regarding which cytokine offers the best sensitivity, specificity, and positive versus negative predictive accuracy, although IL-6 is most often cited in the literature. Elevated IL-6 levels in cord blood and amniotic fluid have been related to adverse long-term neurologic outcomes in the neonate.^93,94  This testing has not become routine, and such diagnostic aids are not used in rural communities.
  • Polymerase chain reaction (PCR) has rapidly developed as a diagnostic aid. It is used to identify microbes such as human immunodeficiency virus, cytomegalovirus, herpes simplex, parvovirus, toxoplasmosis, and bacterial DNA in amniotic and other body fluids. PCR has been used for the diagnosis of amniotic fluid infection caused by bacterial pathogens,⁹⁵ but only university or academic centers may have this technology available to caregivers.
  • Amniocentesis to obtain amniotic fluid carries the risk of rupturing the fetal membranes. For this reason, screening tests that use cervicovaginal secretions to indicate chorioamnionitis have been reported. Potential markers of cervical or chorion inflammation include cervicovaginal secretion concentrations of fetal fibronectin, insulinlike growth factor binding protein-1, and sialidase. Significant association is noted among levels of cervical IL-6, fetal fibronectin, and amnionitis. Conversely, a positive mid gestational fetal fibronectin assay was not associated with acute histologic placental inflammation at birth.⁹⁶  Proteomic profiling of amniotic fluid detects intrauterine inflammation and/or infection and predicts subsequent neonatal sepsis.⁹⁷ Caregivers should follow this research that is not yet widely available in hospitals.   
  • Antenatal screening examinations demonstrate that the presence of group B streptococcal (GBS) colonization increases the risk of chorioamnionitis, and intrapartum prophylaxis with antibiotics reduces the incidence of neonatal infection from GBS.^98,99 Intrapartum screening for GBS using the rapid Streptococcus B test on vaginal secretions identifies more at-risk infants than any other test. The use of the rapid screen for GBS to select mothers who would receive intrapartum chemoprophylaxis may also reduce the cost by approximately $12,000 per prevented case of neonatal infection.¹⁰⁰  More recent studies from Europe have also shown effectiveness of GBS screening and intrapartum chemoprophylaxis, but the investigators have also made suggestions how PCR can improve screening.¹⁰¹
• Examinations of maternal blood
  • WBC counts or C-reactive protein (CRP) levels in maternal blood have been used to predict acute chorioamnionitis when maternal fever is present. Different studies have supported or refuted the use of CRP to diagnose chorioamnionitis.^102,103 The CRP level may be a better predictor of the risk of chorioamnionitis than peripheral WBC counts, especially if the mother has received corticosteroids, which may falsely increase the total WBC count.
  • Other investigators have suggested that the alpha1-proteinase inhibitor complex in maternal blood is a better predictor of amniotic fluid infection than either CRP or WBC count.
    • Analyzing amniotic fluid for leukocytes appears to be a better predictor of amniotic fluid infection than levels of either CRP or total WBC count in maternal blood. In fact, the combination of leukocytosis and a low glucose concentration in the amniotic fluid is highly indicative of chorioamnionitis and may be the best predictor of this condition.
    • Analysis of maternal serum for either IL-6 or ferritin content may also be helpful, because elevations in these mediators are associated with maternal or neonatal infection. Serum IL-6 levels may be more predictive than CRP concentrations in maternal blood.
    • Alpha1-proteinase inhibitor complex, cytokines, and ferritin in maternal blood have not gained widespread use as markers of acute chorioamnionitis.
• The criterion standard for making a diagnosis of early-onset bacteremia, pneumonia, or meningitis in the neonate is the growth of bacteria in an appropriate specimen (ie, blood, tracheal secretions, cerebrospinal fluid [CSF]). Urinary tract infection is an infrequent cause of early onset bacterial disease in the neonate; thus, suprapubic bladder taps are not usually required as part of the evaluation.^104,105
  • In recent years, controversy has arisen regarding the inclusion of the lumbar puncture as part of the evaluation for sepsis. Some clinicians have argued that the neonate with meningitis has obvious manifestations, and the asymptomatic term neonate does not require a lumbar puncture as part of the evaluation for sepsis. Other caregivers argue that a lumbar puncture can only be performed safely when life-threatening pulmonary dysfunction resolves.
  • Other investigators have stressed that cases of meningitis may be missed with this approach.¹⁰⁶ The medical literature contains good evidence that meningitis may exist in association with sterile blood cultures. As meningitis can be such a devastating infection and sterile blood culture in association with no lumbar puncture may result in inadequate therapy for meningitis, a lumbar puncture should continue to be performed as part of the evaluation for neonatal sepsis.
• Studies that are also considered specific for infection include positive findings on Gram stains of CSF or tracheal secretions.¹⁰⁷
  • The tracheal secretions must be obtained shortly after birth (<4-8 h). Both tracheal fluids and CSF should be sterile at birth. The presence of bacteria on microscopic analysis (ie, Gram stain) indicates that more than 10,000 colony-forming units of bacteria are present per milliliter of specimen (body fluid). However, the absence of bacteria in either CSF or tracheal secretions does not exclude infection. A final diagnosis should be made after culture results are available.
  • An absence of neutrophils in CSF or tracheal secretions is expected. The presence of neutrophils in tracheal aspirates obtained after birth indicates that the fetus has mounted an inflammatory response to infection in the environment.
  • Studies by the primary author and separate studies by pathologists indicate that neutrophils present in tracheal secretions shortly after birth originate from the fetus or neonate and do not represent aspirated maternal neutrophils found in infected amniotic fluid.
    • This conclusion is based on examining Y-body fluorescence of the neutrophils present in the tracheal secretions of infected male neonates.
    • In some studies, 50% of the neutrophils present in tracheal secretions of infants with suspected congenital pneumonia had Y-chromosome fluorescence, indicating a fetal origin. 
    • Conversely, 10% of neutrophils in gastric aspirates from the same infants had Y-chromosomal fluorescence. Thus, neutrophils in gastric aspirates are primarily maternal neutrophils, and they represent WBCs present in infected amniotic fluid that is swallowed by the fetus.
    • Alternatively, the flux of fetal airway fluid is outward from the lung. Maternal neutrophils can gain access to the fetal lung only when gasping occurs during fetal asphyxia.
    • The male neutrophils observed in the gastric aspirates of these infants with congenital pneumonia indicated that neutrophils were swallowed after they left the fetal lung via the outward flux of airway fluid.
• Bacterial antigen detection in CSF is also a useful test to indicate bacterial infection. Bacterial antigen detection in the urine should not be a part of the neonate's evaluation for sepsis. Many factors can cause false-positive or false-negative test results in bacterial antigen detection in the urine. Surface cultures have no role in decision-making regarding the diagnosis and treatment of the neonate with early onset bacterial infection.
• All other tests used to diagnose early-onset bacterial infection in the neonate should be considered screening tests. The most common laboratory studies used to screen for neonatal sepsis are WBC profiles and CRP determinations. These tests, at best, are presumptive indicators of infection.
  • WBC profiles (leukopenia [<5000/µL], leukocytosis [>30,000/µL], a markedly diminished absolute neutrophil count [<500-1500/µL], an immature-total neutrophil ratio [>0.3-0.4]) are a commonly used screening test for the septic neonate. Note that the immature-to-total neutrophil ratio of 0.3-0.4 is higher than the previous value of 0.2 reported in the classic studies of Manroe (1977 and 1979).^108,109 Clinical pathologists have been less accepting of the immature-to-total neutrophil ratio as a diagnostic aid in neonatal sepsis.¹¹⁰  
  • Recent studies have reexamined the WBC counts and the leukocyte profiles that are seen in extremely preterm infants¹¹¹ and at high altitude.⁴⁰  Other diagnostic tests (eg, inflammatory factors, adhesion molecules, cytokines, neutrophil surface antigens, or even bacterial DNA) may be superior alternatives to this test. To date, these markers of neonatal inflammation/infection have not replaced leukocyte counts as diagnostic aids.
  • WBC profiles and kinetics are influenced by the genetic makeup of the patient, the gestational age, maternal noninfectious disorders such as pregnancy-induced hypertension (PIH), medications administered to the mother, fetal disease, and many other factors. Reference range WBC counts in the neonate do not exclude infection, and serial studies of WBC indices at approximately 6-hour intervals may be more useful in detecting sepsis.¹¹² A continued assessment of WBC kinetics offers more information regarding decision making. For example, a physician should be particularly concerned when a falling total WBC count, a declining absolute neutrophil count, and a rising immature-to-total neutrophil ratio are observed. This finding may indicate depletion in the bone marrow–related storage pool of neutrophils.¹¹³  
  • Transfusion of neutrophils in this scenario is no longer used because preparation of granulocytes without degranulation of their antimicrobial peptides and downregulation of the respiratory burst is problematic. 
  • The predictive accuracy of WBC indices for the diagnosis of the early onset sepsis (EOS) is poor. Likewise, the accuracy of CRP determinations to predict neonatal infections shortly after birth is low. However, persistently negative findings on CRP may be useful in the decision to stop antibiotic therapy after 48 hours.¹¹⁴
  • Akin to maternal diagnostic studies for infection, alpha1-proteinase inhibitor complex, cytokines (eg, IL-1 and IL-6 in particular, IL-1 receptor antagonist), and detection of bacterial products in neonatal blood have not gained widespread use as markers of neonatal sepsis. However, they may prove to have better predictive accuracy than WBC tests or the CRP. Procalcitonin may have better sensitivity, specificity, and positive and negative predictive value than CRP in the diagnosis of early onset neonatal sepsis.¹¹⁵ None of these tests for EOS are in widespread use, especially in rural hospitals.
  • The study of surface markers of inflammation on leukocytes has provided variable diagnostic use in EOS.^116,117  More research is needed in this field.
  • Molecular methods to identify pathogenic bacteria in neonatal blood have engendered enormous interest because rapid diagnosis is possible.^{118,119,120,121}  Most hospital laboratories do not have the equipment, the wide range of molecular probes, or the trained personnel to accomplish this diagnostic task. Caregivers should pay close attention to field.

Imaging Studies

• Ultrasonography may be used to ascertain fetal well-being. A biophysical profile (BPP) provides information about the status of the fetus. A low BPP score, and especially the loss of fetal breathing movements, has been associated with fetal bacterial infection after premature rupture of membranes.^62,61 Other investigations have not confirmed the importance of a low BPP score, and specifically the absence of fetal breathing, as a reliable test for amnionitis prior to 32 weeks' gestation.^122,123
• Before the fetus is viable, vaginal ultrasonography can be used to identify women with a shortened cervical canal that has been associated with a higher risk of preterm delivery.^124,24,63 Researchers suggest a shortened cervical canal or cervical insufficiency are linked to ascending urogenital infection that initiates premature labor, premature rupture of the membranes, or both.

Other Tests

• The common tests used to diagnose maternal chorioamnionitis are discussed above.
• Tests still in investigational stages and that have not yet come to the bedside are discussed if the testing can reasonably improve clinical outcomes.

Procedures

• Needle aspiration and analysis of amniotic fluid is the only invasive procedure used to confirm diagnosis of acute chorioamnionitis. This procedure can be risky with intact fetal membranes, because the fetal membranes can rupture during or after the procedure.
• Bleeding or placental abruption can also be a consequence of the procedure. The procedure should be performed using ultrasonographic guidance to avoid fetal injury. For these reasons, aspiration of amniotic fluid to diagnose maternal chorioamnionitis has had limited application in obstetric practice.

Histologic Findings

• Gross and microscopic examinations of the placenta, fetal membranes, and umbilical cord for evidence of inflammation and infection are crucial to make a definitive diagnosis of chorioamnionitis.¹³ Histologic chorioamnionitis is a reliable indicator of infection whether or not it is clinically apparent.¹²⁵  Nevertheless, anatomic studies should be correlated with an aseptic culture obtained from the fetal surface of the placenta when caregivers are considering EOS.
• The microbiologic cultures should include an attempt to isolate aerobic and anaerobic bacteria. Special microbiologic techniques may be required for certain microorganisms such as Listeria monocytogenes. Only in these ways can the pathologist help the bedside clinician delineate the cause of maternal chorioamnionitis and neonatal sepsis. Clinicians are encouraged to ask pathologists for help in their search for infections causing disease in the pregnant woman, fetus, and newborn. Obstetricians must also obtain the placenta, fetal membranes, and umbilical cord samples for analytical studies when suspicious clinical circumstances are noted.

Staging

• Redline and colleagues (2003) proposed a scoring system for placental examination that promotes consistency when pathologists judge the severity of chorioamnionitis.¹²⁶
• Several physiologic scores have been proposed for neonates who have life-threatening illness, but a recent report could not conclude that one of those scores accurately predicted neonatal morbidity and mortality during neonatal infection.¹²⁷

Treatment

Medical Care

The observation that epidural anesthesia during labor may create findings suggestive of maternal chorioamnionitis is discussed. A maternal fever that occurs when epidural anesthesia is used during the intrapartum period has often been interpreted as chorioamnionitis. This may not be the case, and the neonate is needlessly treated after birth.

Another discussion addresses the problems of using ampicillin as the chemoprophylactic agent to prevent group B streptococcal (GBS) disease in the neonate. Ampicillin-resistant E coli infections in the mother and her infant are reported as an increasing problem. The use of penicillin rather than ampicillin as the chemotherapeutic agent to prevent GBS infections of the newborn is encouraged.¹²⁸

• Obstetric management influencing neonatal outcome
  • When acute chorioamnionitis is evident, delivery must be expedited. Upon signs of serious fetal distress, delivery must be emergent. Withholding maternal antibiotics to obtain postnatal cultures from the neonate is no longer appropriate. This strategy was once an accepted practice based on the assumption that waiting to obtain cultures from the newborn helps to determine the cause of infection. The morbidity and mortality in the mother and newborn may actually increase because of a delay in administering antibiotics. Studies suggest that obtaining cultures from the mother and beginning antibiotics before delivery probably improves the outcome for the neonate.⁵⁶
  • The physician who cares for such neonates must then decide whether the fetus was infected and whether pretreatment with antibiotics before birth should be continued. The history, physical examination findings, and findings of certain laboratory studies can assist the physician in deciding whether to continue antibiotics started during the intrapartum period. Because antibiotic chemoprophylaxis reduces the risk of GBS infection in neonates, the physician must always consider beginning penicillin during the intrapartum period when a mother has defined risk factors for GBS disease.^129,128 The physician for the infant must judge whether the chemoprophylaxis was sufficient to prevent infection (especially in a healthy, full-term neonate) or whether the infant must continue antibiotic therapy after birth. The US Centers for Disease Control and Prevention (CDC) guidelines outline the strategies for screening and treatment to prevent neonatal disease caused by GBS.^130,98
  • Determining the appropriate procedures in the setting of preterm labor, prelabor, or premature rupture of membranes is more complex. The mother who has preterm labor or premature rupture of membranes and no clinical signs or symptoms of chorioamnionitis should receive prophylactic antibiotics and corticosteroid therapy.³³ Certainly, pregnant women with preterm labor or premature rupture of membranes at 36 weeks' gestation or less should receive prophylactic antibiotics. Mothers at term gestation with accepted risk factors for GBS infection in their fetus should also receive chemoprophylaxis.
  • Some obstetricians have observed little effect of corticosteroids on lung maturity after 32 weeks' gestation, while others have extended the use of corticosteroids to 34 weeks' gestation. Studies have not clearly demonstrated that the use of corticosteroids increases the risk of bacterial infection in the fetus, rather they suggest no added risk.³³
  • The use of intrapartum penicillin or ampicillin is now a recognized therapy to prevent fetal infection or early-onset neonatal infections associated with urogenital colonization by GBS.^131,128 In 1994, Amstey and Gibbs recommended that penicillin G rather than ampicillin be administered to the mother for the prevention of early onset neonatal GBS disease.¹³² Their rationale was that penicillin G chemoprophylaxis does not increase colonization of the urogenital tract with ampicillin-resistant gram-negative bacteria. This assumption now seems correct, based on a recent report showing intrapartum ampicillin did not increase neonatal infections caused by ampicillin-resistant E coli.⁷
  • Conversely, recent reports showed an increased occurrence of infections caused by ampicillin-resistant E coli in premature neonates.^133,134 These mothers had received ampicillin for chemoprophylaxis rather than penicillin, and these authors again recommended use of intrapartum penicillin to prevent fetal or early onset neonatal infections with GBS.
• Neonatal immunology and the risks created by maternal chorioamnionitis
  • Newborns are vulnerable to infection because of an immature or underdeveloped immune system.¹³⁵ Factors that render neonates susceptible to bacterial infections include reduced numbers and/or function of macrophages and dendritic cells in peripheral tissues (eg, lung); lower numbers of neutrophils in the bone marrow storage pool;¹¹³ decreased immunoglobulin G (IgG) and complement levels, especially in prematurely born infants; an inability to respond to bacterial carbohydrate antigens; an increased percentage of T cells bearing naïve cell surfaces and correspondingly underdeveloped functional behaviors related to foreign antigens; and anatomic and biochemical immaturity of skin and mucosal barriers (eg, lung and gut epithelia) as they relate to local host defenses.
  • Emerging treatments, such as the use of intravenous immunoglobulins and hematopoietic growth factors, may correct deficiencies of the neonatal immune system.¹³⁶ The use of immunotherapy still requires more investigation before these treatments become a standard of care.¹³⁷  However, the mainstays of current neonatal intensive care for bacterial sepsis in neonates continue to be prompt recognition of bacterial infection, antimicrobial therapy, and supportive care.
• Treatment of the neonate
  • Communication between obstetric and pediatric caregivers is essential to recognize neonatal infection.
  • Recognition or suspicion of maternal chorioamnionitis is essential to reducing neonatal morbidity and mortality caused by early-onset bacterial infections in the neonate. Nurses and physicians who care for the mother must communicate their concerns about maternal infection to the nurses and physicians who care for the newborn after birth. Caregivers in the nursery must be critically aware of a neonate's signs and symptoms in relationship to the antepartum and intrapartum history.
  • Signs and symptoms in the mother that suggest chorioamnionitis and increase the risk of fetal or neonatal infection are described in Physical. Although numerous ways to approach the diagnosis and treatment of neonatal sepsis are recognized, a hands-on assessment is the main key to recognition. The experienced physician or nurse in the nursery may indicate to fellow caregivers that the newborn has a septic appearance.

Surgical Care

Surgical interventions are infrequently required in early onset bacterial infections of the neonate. The conditions that may require intervention include epidural or brain abscess, subcutaneous abscesses, infections localized to the pleural space, certain intra-abdominal infections (especially if intestinal perforation is present), and bone or joint infections.

Consultations

Depending on the hospital setting and the status of the neonate, a family physician may seek a pediatric consultation. Depending on the severity of infection, other neonatal diseases, and the hospital in which the newborn is located, the pediatrician may seek consultation with a neonatologist, a pediatric infectious disease subspecialist, or both. If organ system failure is present or impending organ system failure (eg, respiratory, cardiovascular, renal) secondary to infection is a concern, the infant should be transferred to an appropriate level 3 or level 4 neonatal intensive care unit (NICU). Transportation to a level 3 or 4 NICU is clearly indicated for extremely premature infants requiring high-frequency oscillatory ventilation or near-term or term neonates nearing criteria for extracorporeal membrane oxygenation (ECMO).

Diet

Seriously or critically ill newborns with early-onset bacterial infections require parenteral fluids and nutrition until their condition improves. Infections involving the GI tract may need a special approach to feeding when feedings are reinstituted.

Activity

Activity and illness is generally related to adults, but neonates are typically at rest and are not stressed when seriously or critically ill.

Medication

Early delivery, supportive care, and antibiotic administration for the mother with chorioamnionitis are discussed in Medical Care. The antibiotics used most often to treat mothers with acute chorioamnionitis are also discussed.⁵⁶

The treatment of bacterial vaginosis has also been discussed above; however, antibiotic therapy for this condition is often not successful.^138,139

The treatment of the potentially septic neonate is complex. An overview of the treatment for early onset neonatal infection is summarized in Medical Care.

Maternal antibiotics for chorioamnionitis

The standard drug treatment in the mother with chorioamnionitis includes ampicillin and an aminoglycoside (ie, usually gentamicin), and potential addition of clindamycin.⁵⁶ Clindamycin is used if the mother is allergic to penicillin, although some experts propose use of a cephalosporin. In cases involving premature labor or premature rupture of membranes, ampicillin is frequently administered as a chemotherapeutic agent to prevent group B streptococcal (GBS) colonization of the fetus. The use of penicillin alone is suggested for GBS chemoprophylaxis during the intrapartum period. Using penicillin rather than ampicillin may avoid colonization of the fetus with ampicillin-resistant E coli. The rationale for ampicillin use when maternal chorioamnionitis is suspected is that ampicillin would treat GBS, Haemophilus species, many enterococci strains, and L moncytogenes. For more information on intrapartum antibiotic use to prevent GBS, see the eMedicine topic Bacterial Infections and Pregnancy.

Clindamycin may treat S aureus and anaerobes. Gentamicin provides broad-spectrum coverage against gram-negative bacteria. These antibiotics should be intravenously administered. The drugs mentioned above are generally safe for mother and fetus. An absolute contraindication in using these antibiotics is a known allergic reaction to them. Renal function must always be considered when using antibiotics, especially aminoglycosides.

If a urinary tract infection is present, the appropriate antibiotic or combination of antibiotics should be used to treat the specific bacterium isolated from the urine.

Erythromycin is infrequently used in women allergic to penicillin. Its ability to enter urogenital secretions has been questioned, especially in the treatment of Ureaplasma urealyticum -related or Mycoplasma hominis -related colonization in pregnant women.

Of the invasive GBS strains that were isolated in one study, resistance to either clindamycin or erythromycin was in excess of 20%, whereas colonizing isolates of GBS had resistance of more than 40%.¹⁴⁰  A report from the CDC noted that, of 4882 isolates of GBS, 15% and 32% were resistant to clindamycin and erythromycin, respectively.¹⁴¹  This suggests that erythromycin or clindamycin used as chemoprophylaxis to prevent GBS infection in neonates born to women with penicillin allergy may not always be successful.

Dosages of antibiotics to treat maternal chorioamnionitis are not provided because this is a pediatric review addressing maternal chorioamnionitis as it affects the newborn infant.

Supportive, immune, and antibiotic therapy of early onset bacterial infection

An extensive discussion of the management of septic neonates is not possible in this article but is available in other eMedicine chapters (see Neonatal Sepsis). Critical points to ensure intact survival of the neonate are mentioned for completeness. For example, ventilator management and surfactant replacement therapy can be used to treat the neonate with congenital bacterial pneumonia, but a complete discussion of the techniques involved in this therapy are covered in other articles. Physicians and nurses attending the delivery of a newborn whose mother is suspected of having chorioamnionitis should be ready to perform a full resuscitation, including intubation, providing positive-pressure ventilation, and treatment of hypovolemia, shock, and acidosis. Low Apgar scores may be another indicator of sepsis. After initial stabilization of a neonate with potential infection in the delivery room, direct attention toward the following variables that influence survival:

• Warmth, monitoring of vital signs, and maintenance of fluid, electrolyte balance, and correction of significant metabolic acidosis
• Management of the circulation, including correction of hypovolemia and enhancement of cardiac performance with inotropic drugs if sepsis-related myocardial dysfunction is noted
• Glucose homeostasis
• Treatment of respiratory distress that may entail surfactant replacement (for pneumonia, respiratory distress syndrome) and different modes of assisted ventilation (Inhaled nitric oxide may be considered as a therapy in the presence of pulmonary hypertension.)
• Assessment and treatment of thrombocytopenia and coagulopathy, if present

The aforementioned elements of supportive care are essential to reducing morbidity and mortality. When myocardial dysfunction, cardiovascular collapse, and severe pulmonary hypertension are not reversible, extracorporeal membrane oxygenation (ECMO) may be a life-saving intervention. In critically ill septic neonates, the importance of early referral for ECMO cannot be overstated.

Pulmonary hypertension can complicate the management of neonatal sepsis, and inhaled nitric oxide may reverse this complication. The use of inhaled nitric oxide in a non-ECMO facility may be problematic. This is particularly true if the septic neonate deteriorates and must be transferred to an ECMO facility while on inhaled nitric oxide therapy. The referring facility may not have the capability to provide inhaled nitric oxide during transport to the ECMO facility. In this circumstance, the seriously ill infant may become critically ill with the cessation of inhaled nitric oxide therapy during transport. Therefore, guidelines for referral to an ECMO center should be established for each neonatal ICU (NICU) based on the center's own resources and ability to safely transport such infants.

Guidelines for immunotherapy in early onset sepsis (EOS) are not well established. Treatments used include administration of granulocyte or granulocyte-macrophage colony-stimulating factors (eg, filgrastim, sargramostim); intravenous administration of immunoglobulin G (IgG), particularly if a high-titer IgG antibody against a specific bacterial pathogen is available; and leukocyte transfusions for depletion of neutrophils in the bone marrow storage pool. Despite research on each of these immunotherapies, no agreement regarding their use has been reached. A neonatologist, pediatric infectious disease subspecialist, or both should be consulted if immunotherapy is contemplated.

Antibiotic therapy for early onset bacterial infection of the neonate usually includes the administration of a penicillin (ie, ampicillin is most often used for additional coverage against Haemophilus species, enterococci, and listeriosis) and an aminoglycoside (ie, usually gentamicin). Generally, gentamicin provides ample coverage against gram-negative bacteria that cause EOS. The third-generation cephalosporins should be used as part of the antibiotic regimen if resistant E coli is suspected based on maternal history, amniotic fluid cultures, and the clinical picture. Cefotaxime has been advocated by some experts when meningitis is suspected or when an asphyxiated infant or an extremely preterm infant is being treated and severe renal dysfunction may be present. 

Antibiotic administration in newborns is based on birth weight criteria and gestational age at birth. Doses of antibiotics change with increasing postnatal age and improving renal function. Administration of aminoglycosides should include changes in dosing based on pharmacokinetics.

Final decisions about antibiotics should be based on positive culture results from appropriate anatomic sites. If renal dysfunction is present, antibiotic dosages should be adjusted during the course of their administration. This is particularly true for aminoglycoside administration in extremely premature newborns and in newborns with urogenital anomalies.

Recommendations on the appropriate antibiotic dose can be found in neonatology handbooks (ie, Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs or Manual of Neonatal Care) and textbooks of neonatal-perinatal medicine. Specific textbooks about antibiotic use in pediatric patients, including neonates (ie, Nelson's Pocketbook of Pediatric Antimicrobial Therapy), have also been written. For this article, the NEOFAX 2008 was used for selecting the dose per kilogram and interval between the administration of doses for specific antibiotics. The information on antibiotics is not exhaustive and the antibiotics discussed are those most likely to be used in EOS.

Lastly, the physician must consider the duration of antibiotic therapy. This is particularly true when deciding the duration of antibiotic treatment for well-appearing term neonates. In the era of managed care, in which cost reductions are typical, discontinuing antibiotics in healthy term neonates within 24-48 hours of initiating therapy is probably safe. With current bacteriologic techniques, more than 90-95% of neonatal blood cultures become positive within 48 hours of the time they are obtained. In conjunction with screening tests, such as a negative C-reactive protein (CRP) result that is measured at 48 hours after birth, discontinuing antibiotic treatment and discharging the well-appearing term neonate would be appropriate.

In neonates with proven infection, the well-being of the infected newborn should guide the duration of antibiotic therapy. The bacterium causing the infection and the site of the infection also influence the duration of antibiotic therapy. For example, bacterial pneumonia is often treated for 7-10 days with antibiotics. Bacteremia is often treated with antibiotics for 10-14 days. Because of the potential for recurrence with shorter courses of treatment, 10 days of antibiotics is often considered a minimum for GBS-associated bacteremia.

Cerebrospinal fluid (CSF) infections may require antibiotic therapy for 2-4 weeks based on the bacterium responsible for the infection, findings on an analysis of CSF indicating the resolution of infection, and the presence of complications associated with meningitis. For uncomplicated GBS-related infections of the CSF, 2 weeks may be sufficient; other gram-positive and all gram-negative bacteria require 3-4 weeks of antibiotic therapy. Surgical interventions for localized CNS infections (eg, an infectious epidural collection, brain abscess) or the presence of postinfectious hydrocephalus may indicate antibiotic therapy needs to be provided for as long as 4 weeks.

The following information reviews the antibiotics that are commonly used to treat early onset bacterial infections in the neonate. The antibiotics covered are not exhaustive. For example, the use of azithromycin to treat congenital pneumonia caused by Urealyticum in extremely premature newborns and the use of vancomycin to treat catheter-related nosocomial bacteremia are not reviewed. Issues related to these and other specific bacterial infections of neonates require consultation with a neonatologist or a pediatric infectious diseases subspecialist.

Antibiotic Agents

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the clinical setting. Antibiotic combinations are usually recommended for serious Gram-negative bacillary infections. This approach ensures coverage for a broad range of organisms and polymicrobial infections. In addition, it prevents resistance from bacterial subpopulations and provides additive or synergistic effects. Once organisms and sensitivities are known, the use of antibiotic monotherapy is then recommended. Information about antimicrobials used to treat neonates and the source for this review is NEOFAX 2008.¹⁴²

Aqueous crystalline penicillin G or ampicillin are considered first-line agents for GBS. Other modified penicillins such as oxacillin or nafcillin (antistaphylococcal), netilmicin (antipseudomonal or other Gram-negative enteric bacteria), and piperacillin (antipseudomonal) are not typically used as first-line antibiotics for treatment of early onset neonatal infections. The aforementioned modified penicillins are designed to treat infections caused by penicillin-resistant bacteria that can express beta-lactamase. These modified penicillins are usually reserved for the treatment of postnatally acquired infections in hospitalized neonates. Methicillin-resistant staphylococcal infections have emerged in pregnant women, and neonates with EOS who have these staphylococci are reported; such infections require treatment with vancomycin.

Ampicillin

A more broad-spectrum aminopenicillin used for many years as either a definitive or a prophylactic therapy for early onset bacterial infection of neonates. May provide additional coverage against Haemophilus species, many enterococci, other streptococci, Listeria monocytogenes, and a limited number of susceptible gram-negative enteric bacteria. Indicated for neonatal bacteremia or meningitis due to GBS.

Dosing

Adult

Pediatric

Bacteremia: 25-50 mg/kg/dose IV/IM q12h
Meningitis or severe GBS infections: 100 mg/kg/dose IV q12 h

Interactions

Admixture incompatibilities may occur (eg, dextrose 10% solution, amino acids, amikacin, amiodarone, erythromycin lactobionate, fluconazole, gentamicin, hydralazine, metoclopramide, midazolam, nicardipine, tobramycin)
Compatible with 5% dextrose and 0.9% NaCl; terminal injection site compatibility via Y-site administration includes fat emulsion, acyclovir, aminophylline, calcium gluconate, heparin, dopamine, furosemide, insulin, KCl, sodium bicarbonate, ranitidine, and vancomycin

Contraindications

Documented hypersensitivity; anaphylactic shock mediated by penicillin-related allergy (rare in neonates); bacterial resistance to ampicillin (use other antibiotics)

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Rapid administration of high doses can cause seizures; morbilliform or blotchy rash related to ampicillin infrequently observed (must rule out cytomegalovirus infection as cause for this type of rash); thrush or diaper dermatitis caused by a secondary infection with Candida species is particularly common with ampicillin-related use; may alter intestinal flora and cause diarrhea (also consider antibiotic-related colitis as a cause of diarrhea); rare adverse effects include drug fever, serum sickness, or reduced leukocyte or platelet numbers (caused by bone marrow suppression or idiopathic)

Penicillin G, aqueous crystalline (Pfizerpen)

Do not confuse with benzathine or procaine penicillin used only for IM injections; penicillin G is the original antibiotic in the penicillin class. Penicillin G is recommended for treatment of GBS infections. Penicillin G may provide adequate coverage for Streptococcus pneumoniae when it is a cause of early onset bacterial infection in neonates (infrequent) but this bacterium can also have resistance to penicillin G.

Dosing

Adult

Pediatric

Bacteremia: 25,000-50,000 U/kg/dose IV infused over 15 min or IM
Meningitis: 75,000-100,00 U/kg/dose IV infused over 30 min or IM; before 44 weeks' gestation, the dosing interval is q12h for early onset neonatal infections
For GBS infections, some experts recommend using penicillin G at doses of 200,000 U/kg/d IV divided q12h for bacteremia and 450,000 U/kg/d IV divided q12h for meningitis

Interactions

Admixture incompatibility with amikacin, aminophylline, amphotericin B, gentamicin, hydralazine, metoclopramide, netilmicin, and tobramycin
Compatible with 5% dextrose, 10% dextrose, and 0.9% NaCl
Compatible at terminal injection via Y-site with dextrose and amino acid solutions, fat emulsion, acyclovir, amiodarone, caffeine citrate, calcium chloride, calcium gluconate, dopamine, fluconazole, furosemide, heparin, hydrocortisone succinate, methicillin, metronidazole, morphine, phenobarbital, KCl, prostaglandin E1, ranitidine, and sodium bicarbonate

Contraindications

Documented hypersensitivity; anaphylactic shock mediated by penicillin-related allergy (rare in neonates); bacterial resistance (use other antibiotics)

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Adverse effects include allergic rashes related to penicillin G (rare in neonates); rare adverse effects include drug fever, serum sickness, or reduced leukocyte or platelet numbers (caused by bone marrow suppression or idiopathic); high dose and rapid infusion can cause cardiac arrest or CNS toxicity

Cefotaxime (Claforan)

A third-generation cephalosporin with enhanced potency against many gram-negative bacteria. Generally considered inactive against enterococci, Listeria, and most strains of pseudomonads and bacteroides. Some experts consider this antibiotic the preferred therapy for neonatal meningitis caused by gram-negative bacteria if the bacterium is sensitive to it (and in conjunction with an aminoglycoside). This preference is based on more effective CNS penetration of cefotaxime. Indicated when aminoglycosides may be contraindicated (eg, significant renal failure) or when aminoglycosides may have enhanced toxicity.

Dosing

Adult

Pediatric

50 mg/kg/dose IV q12h infused over 30 min or administered IM; before 44 wk of gestation, the dosing interval is q12h

Interactions

May increase the nephrotoxicity of aminoglycosides and loop diuretics (eg, furosemide); compatible with 5% dextrose, 10% dextrose, and 0.9% NaCl; compatible at terminal Y-site with amino acids, fat emulsion, aminophylline, caffeine citrate, heparin, KCl, lorazepam, and morphine
Incompatible when admixed with aminophylline, fluconazole, sodium bicarbonate, and vancomycin (conflicting data, vancomycin may be compatible with cefotaxime in low concentration)

Contraindications

Documented hypersensitivity (absolute contraindication but extremely rare in neonates); bacterial resistance (use other antibiotics); presence or potential for severe renal dysfunction (eg, extreme prematurity, severe birth asphyxia, known and severe renal malformations)

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Third-generation cephalosporins may alter microbial flora on mucosal surfaces (thus, PO infections and genital dermatitis with Candida species must be identified and treated promptly); routine use of cefotaxime (rather than an aminoglycoside) in evaluations to rule out neonatal sepsis or in prolonged treatment of proven or unproven gram-negative bacterial infections may result in the emergence of gram-negative bacterial flora in NICUs that are resistant to multiple cephalosporins; pain may be more intense after IM injection of cephalosporins; cephalosporins may cause thrombophlebitis during IV administration; cefotaxime can cause antibiotic-related pseudomembranous colitis (eg, infections caused by Clostridium difficile); adverse effects include rash, phlebitis, diarrhea, leukopenia, granulocytopenia, and eosinophilia

Gentamicin

Gentamicin is one of the aminoglycoside antibiotics (ie, amikacin, netilmicin, and tobramycin). Generally, gentamicin has activity against Pseudomonas aeruginosa, whereas kanamycin does not. First choice for prophylactic or definitive therapy of early-onset bacterial infections in neonates because it has broad activity against many gram-negative bacilli. Amikacin and tobramycin are usually reserved to treat nosocomial infections caused by gram-negative bacteria that are resistant to gentamicin.
Aminoglycosides should not be used alone to treat infections potentially caused by gram-positive bacteria. Thus, penicillin is always included in the treatment of early onset bacterial infections in neonates. Furthermore, to prevent the emergence of highly antibiotic-resistant gram-negative bacteria, nosocomial infections in hospitalized neonates should never be treated with an aminoglycoside alone. A second antibiotic should be administered in addition to the aminoglycoside, and its mechanism of action that causes microbial death should be different from that of the aminoglycoside.
Elevated blood concentrations of aminoglycosides may cause significant injury to the kidney and vestibular and auditory nerve. Concurrent use of furosemide or other loop diuretics and use of vancomycin can increase nephrotoxicity. Thus, peak and trough levels of aminoglycosides in neonatal sera must be measured if their use is going to exceed an initial period of prophylaxis (48 h after birth) to exclude sepsis.
Aminoglycosides demonstrate concentration-dependent killing of bacteria, suggesting a potential benefit related to higher serum concentrations that are achieved with less-frequent dosing (eg, once daily administration).

Dosing

Adult

Pediatric

Postmenstrual age <29 weeks: 5 mg/kg IV q48h during the first 7 d of life
Postmenstrual age 30-34 weeks: 4.5 mg/kg IV q36h during the first 7 d of life
Postmenstrual age >35 weeks: 4 mg/kg IV q24h during the first 7 d of life
IV administration is preferred because IM doses have variable absorption, especially in extremely preterm infants; infuse IV over 30 min

Interactions

Antipseudomonal penicillins may decrease serum aminoglycoside concentrations, especially if renal failure is present; coadministration with other aminoglycosides, cephalosporins, penicillins, vancomycin, and amphotericin B may increase nephrotoxicity; aminoglycosides enhance effects of neuromuscular blocking agents (eg, pancuronium, magnesium sulfate) and prolonged respiratory depression may occur; coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (regularly monitor blood levels of the aminoglycoside)
Compatible with 5% dextrose, 10% dextrose, and 0.95 NaCl; examples of terminal injection Y-site compatibility include dextrose and amino acid solutions, fat emulsion, acyclovir, caffeine citrate, clindamycin, dopamine, famotidine, fluconazole, insulin, lorazepam, heparin (<1 unit/mL), magnesium sulfate, methicillin, morphine, oxacillin, prostaglandin E1, vecuronium, and zidovudine
Examples of admixture incompatibility include amphotericin B, ampicillin, cefepime, furosemide, imipenem/cilastatin, heparin (<1 U/mL), indomethacin, oxacillin, mezlocillin, nafcillin (conflicting reports), penicillin G, propofol, and ticarcillin/clavulanate

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

Precautions

Bacterial resistance mandates selection of another aminoglycoside, third-generation cephalosporin, a beta-lactamase–resistant penicillin, or a combination for therapy; after 48 h, monitor a serum peak level (obtain 30 min after dose administered) and serum trough level (just prior to next dose); with prolonged therapy, determine what peak levels of gentamicin the hospital laboratory considers therapeutic and what trough levels are considered toxic (ask the pharmacist for recommendations in changing the dose and/or the interval of gentamicin when peak and/or trough levels of gentamicin are out of range); monitor urinalysis and serum BUN and creatinine concentrations for signs of nephrotoxicity (abnormalities in these test results are late signs of aminoglycoside-related nephrotoxicity) based on increased urinary concentrations of enzymes released from renal epithelial cells; aminoglycoside-related toxicity occurs long before abnormalities in the urinalysis or blood BUN/creatinine concentration are present; well-appearing neonates who have negative bacterial culture results and normal CRP levels in blood usually do not require treatment with antibiotics 48 h after birth

Follow-up

Further Inpatient Care

• Both the mother with suspected chorioamnionitis and her newborn with suspected sepsis require frequent assessments over the first 48 hours following birth. Mothers with chorioamnionitis who appear well after a brief intravenous course of antibiotics may be discharged on oral antibiotic therapy, but thorough outpatient follow-up care is required. General and gynecologic health is usually normal after maternal chorioamnionitis.
• Term neonates undergoing an evaluation to exclude sepsis who consistently appear well can probably go home with their mothers within 48 hours after birth.

Further Outpatient Care

• Depending on the nature of the infection and other risk factors associated with the hospitalization (eg, extreme prematurity, need for home oxygen), an outpatient follow-up visit may be scheduled from 1 day to 2 weeks after discharge. Home health care follow-up visits by a reliable and well-trained nursing service may also be indicated.

Inpatient & Outpatient Medications

• Outpatient antibiotics used to treat a term neonate with rule-out sepsis have not been evaluated. Some managed care plans have discharged neonates with proven infection who appear well after antibiotic therapy. These newborns complete a course of intravenous antibiotics at home. The intravenous antibiotics are often administered via a percutaneous venous line placed before hospital discharge. A visiting nurse comes to the home to administer the antibiotics twice daily.
• Depending on the type of infection found in the neonate, the duration of intravenous therapy with antibiotics ranges from 7 days (eg, perhaps pneumonia with rapid improvement) to 4-6 weeks (eg, osteomyelitis). The actual duration of treatment for different types of neonatal infections has not been studied. The duration of treatment for neonatal infections is often based on experience rather than evidence-based.

Transfer

• Infected neonates born at hospitals with level 1 (normal) or level 2 (special care) nurseries may require transfer to a level 3 or 4 neonatal ICU (NICU).
• Transfer depends on the circumstances of the neonatal infection, degree of prematurity, presence of anomalies, and other pathophysiologic states.
• Reasons for transfer of the neonate from a level 1 or 2 nursery to a higher-level facility are outlined in Consultations.
• Transfer requirements such as oxygen or assisted ventilation, mode of transportation (eg, ambulance, helicopter, fixed wing aircraft), and health care personnel to transport the patient are beyond the scope of this article.

Deterrence/Prevention

• Maternal antibiotic chemoprophylaxis is related to urogenital colonization with group B streptococcus (GBS). Mothers are screened for GBS-related colonization at 35-37 weeks' gestation. Preterm labor before 35 weeks' gestation means that knowledge of GBS-related colonization of the urogenital tract is not immediately available. The CDC has published guidelines for "Prevention of Perinatal Group B Streptococcal Disease."¹³⁰
• GBS-related chemoprophylaxis is the program of this type related to maternal chorioamnionitis. Treatment bacterial vaginosis to prevent preterm birth has been considered, although its effectiveness is questioned. When a mother has signs and symptoms of chorioamnionitis during the intrapartum period, the administration of antibiotics is warranted to treat not only the mother but also her fetus, which may have acquired infection because of the placental disease.

Complications

• For the mother with chorioamnionitis, serious infectious complications include endometritis, localized pelvic infections requiring drainage, and intra-abdominal infections. Maternal chorioamnionitis or other secondary infectious complications may cause thrombosis of pelvic vessels and the potential for pulmonary emboli.
• Serious complications, including septic shock, pulmonary hypertension, respiratory failure, and meningitis, occur in early onset bacterial infections of the neonate. The duration of hospitalization can be quite prolonged in an extremely premature infant because of infectious complications such as maternal chorioamnionitis or congenital pneumonia. Either condition increases the probability of chronic lung disease in prematurely born and term babies.^143,40,144

Prognosis

• The outcome of neonatal infections depends on the causative organism, nature of infection, time of infection onset to administration of appropriate therapy, symptoms at time of birth, and gestational age of the infant. Prematurity and birth defects are cofactors that must be considered when a prognosis is offered to parents or caregivers of an infected newborn. When each of these factors is considered, a prognosis may be provided.
• Outcome may not be evident during the neonatal period, and long-term follow-up care is indicated in these infected neonates. Thus, referring these infants to a neonatal follow-up clinic after discharge is prudent. Parental permission should be obtained for transfer of health-protected information because records of the maternal and neonatal course assist in delineating neurologic pathophysiology.

Patient Education

• Parents or other caregivers of infected neonates need specific instructions about their subsequent care. This is particularly true for secondary complications associated with these infections. For example, caregivers of an infant with meningitis that has postinfectious hydrocephalus requiring a ventriculoperitoneal shunt placement needs to have specific instructions about shunt-related malfunction or shunt-related infection.
• Similarly, caregivers of patients with long-term pulmonary complications of congenital pneumonia may require specific education (eg, administration of oxygen or use of bronchodilators at home). Parental education in neonatal resuscitation is indicated for many graduates of the NICU.

Miscellaneous

Medicolegal Pitfalls

• In the United States, civil litigation is an increasing threat to health care professionals.¹⁴⁵ This is particularly true for obstetricians and neonatologists, but these caregivers have ways to avoid the experience.^146,145,147
• The initial signs and symptoms of neonatal infections may be subtle or absent; they may be followed by a rapid and devastating course. The potential for severe disability or death as a consequence of neonatal bacterial infection has resulted in the treatment of one infected infant out of 20 infants who received initial therapy but had no proven disease. The evaluation to exclude sepsis is a classic example of the difficulty in differentiating infants with infection from those who are not infected. Antibiotic therapy for early onset neonatal sepsis is a classic example of family practitioners and pediatricians practicing defensive medicine. If the diagnosis and treatment of obvious meningitis and sepsis are missed in the neonate, physicians, other health care professionals, and the hospital face significant medicolegal risk.¹⁴⁸
• The importance of chorioamnionitis takes on added medicolegal significance because several carefully controlled studies demonstrate an association between intrauterine infection and cerebral palsy in term infants.^149,43 The relationship has also been demonstrated in preterm infants.^150,151 The legal profession now sees an opportunity for litigation, and attorneys are filing frivolous lawsuits that suggest earlier antibiotic therapy could have mitigated cerebral palsy. This is not the circumstance. Recently, an article in Clinics in Perinatology discussed how caregivers can facilitate better understanding by parents of their infant's condition during hospitalization in the neonatal ICU (NICU).¹⁵²  
• Honest and empathetic communication with parents about the critical condition of their preterm infant, or any infant in a NICU, can help to avoid litigation. Documentation of both the infant's overall disease state and a conversation with the parents about their infant's condition in the medical record are two essential elements in preventing litigation.

Special Concerns

• Epidural anesthesia
  • The adverse effects of epidural anesthesia on the mother and her newborn continue to be an unresolved. Labor may be prolonged by epidural anesthesia;⁶⁸ thus, mothers who receive this type of anesthesia may become dehydrated and exhausted. These women may develop an elevated temperature during epidural anesthesia;¹⁵³ in turn, their fetus may have an increased heart rate associated with epidural anesthesia and maternal fever. The presence of maternal fever and fetal tachycardia initiate an investigation of the cause, and the obstetrician often administers antibiotics thereafter. Intermittent labor analgesia reduces the incidence of maternal fever more than continuous epidural analgesia.¹⁵⁴
  • The neonate may be born in a febrile state.⁶⁵  Typically, newborns appear and act healthy after intrapartum epidural anesthesia. Elevated temperature in neonates rapidly returns to normal in babies without infection. Controversy surrounds conducting an evaluation for sepsis in neonates with this history. Some pediatricians or family practitioners may elect to perform an evaluation for sepsis and treat for 48-72 hours with antibiotics pending the culture results. Controversy also surrounds performing a lumbar puncture as part of every evaluation for sepsis in a well-appearing term newborn who may have bacteremia. In cases involving a mother who had epidural anesthesia and an elevated temperature during labor, many pediatricians and neonatologists may not perform a lumbar puncture as part of the evaluation for sepsis.
  • Despite the observation that most febrile infants are well after a mother has epidural anesthesia during labor, an assessment nevertheless should be cautious. Neonatal fever after delivery involving epidural anesthesia can have seizures, other forms of encephalopathy, and other adverse outcomes.^66,155
  • Fever associated with epidural anesthesia in the absence of chorioamnionitis can be confirmed based on placental histology and microbiologic culture findings.
• Urogenital infections
  • A major and unresolved problem during pregnancy is urogenital infections caused by Ureaplasma urealyticum and Mycoplasma hominis. The high percentage of cord blood-related cultures positive for Ureaplasma urealyticum and Mycoplasma hominis is a recent and disturbing trend. These positive cultures were strongly associated with placental inflammation and preterm birth.¹⁵⁶  
  • The lung of very preterm infants were also inflamed from intrauterine infection with U urealyticum and M hominis and appears related to the pathogenesis of bronchopulmonary dysplasia.
  • Infections that may be addressed by use of doxycycline plus azithromycin after cesarean delivery¹⁵⁷ cannot be used in preterm neonates because of potential toxicity.¹⁵⁸  
  • Effective antibiotic therapy of U urealyticum and M hominis in preterm neonates has yet to be realized, and controlling inflammation in the infected, immature lung of human infants remains problematic.

This article is an introduction to the topic of bacterial infections during pregnancy and subsequent bacterial infections of the fetus and newborn. The subject is expansive in scope, and readers are encouraged to seek more information from other sources. Other articles of interest include Congenital Pneumonia; Meningitis, Bacterial; and Neonatal Sepsis.

References

1. Escobar GJ. The neonatal "sepsis work-up": personal reflections on the development of an evidence-based approach toward newborn infections in a managed care organization. Pediatrics. Jan 1999;103(1 Suppl E):360-73. [Medline].

2. Callaghan WM, MacDorman MF, Rasmussen SA, Qin C, Lackritz EM. The contribution of preterm birth to infant mortality rates in the United States. Pediatrics. Oct 2006;118(4):1566-73. [Medline].

3. Larsen JW, Sever JL. Group B Streptococcus and pregnancy: a review. Am J Obstet Gynecol. Apr 2008;198(4):440-8; discussion 448-50. [Medline].

4. Baltimore RS. Consequences of prophylaxis for group B streptococcal infections of the neonate. Semin Perinatol. Feb 2007;31(1):33-8. [Medline].

5. Stoll BJ, Hansen NI, Higgins RD. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J. Jul 2005;24(7):635-9. [Medline].

6. Bizzarro MJ, Dembry LM, Baltimore RS, Gallagher PG. Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics. Apr 2008;121(4):689-96. [Medline].

7. Schrag SJ, Hadler JL, Arnold KE, Martell-Cleary P, Reingold A, Schuchat A. Risk factors for invasive, early-onset Escherichia coli infections in the era of widespread intrapartum antibiotic use. Pediatrics. Aug 2006;118(2):570-6. [Medline].

8. Bratu S, Eramo A, Kopec R. Community-associated methicillin-resistant Staphylococcus aureus in hospital nursery and maternity units. Emerg Infect Dis. Jun 2005;11(6):808-13. [Medline].

9. Andrews WW, Schelonka R, Waites K, Stamm A, Cliver SP, Moser S. Genital tract methicillin-resistant Staphylococcus aureus: risk of vertical transmission in pregnant women. Obstet Gynecol. Jan 2008;111(1):113-8. [Medline].

10. Hollier LM, Wendel GD Jr [Editors]. Infectious Diseases in Pregnancy. Clin Perinatol. 2005;32 (3):523-814.

11. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel L, Hassan S. The role of inflammation and infection in preterm birth. Semin Reprod Med. Jan 2007;25(1):21-39. [Medline].

12. Romero R, Gotsch F, Pineles B, Kusanovic JP. Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr Rev. Dec 2007;65(12 Pt 2):S194-202. [Medline].

13. Reilly SD, Faye-Petersen OM. Chorioamnionitis and Funisitis: Their Implications for the Neonate. NeoReviews [serial online]. September 2008;9:e411-e417. Available from: American Academy of Pediatrics. Accessed September 21, 2008. Available at http://neoreviews.aappublications.org/cgi/content/full/neoreviews;9/9/e411.

14. Hitti J, Hillier SL, Agnew KJ, Krohn MA, Reisner DP, Eschenbach DA. Vaginal indicators of amniotic fluid infection in preterm labor. Obstet Gynecol. Feb 2001;97(2):211-9. [Medline].

15. Al-Adnani M, Sebire NJ. The role of perinatal pathological examination in subclinical infection in obstetrics. Best Pract Res Clin Obstet Gynaecol. Jun 2007;21(3):505-21. [Medline].

16. Anderson BL, Simhan HN, Simons KM, Wiesenfeld HC. Untreated asymptomatic group B streptococcal bacteriuria early in pregnancy and chorioamnionitis at delivery. Am J Obstet Gynecol. Jun 2007;196(6):524.e1-5. [Medline].

17. Hakansson S, Kallen K. High maternal body mass index increases the risk of neonatal early onset group B streptococcal disease. Acta Paediatr. Oct 2008;97(10):1386-9. [Medline].

18. [Best Evidence] Swadpanich U, Lumbiganon P, Prasertcharoensook W, Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst Rev. Apr 16 2008;CD006178. [Medline].

19. [Best Evidence] McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. Jan 24 2007;CD000262. [Medline].

20. Siqueira FM, Cota LO, Costa JE, Haddad JP, Lana AM, Costa FO. Intrauterine growth restriction, low birth weight, and preterm birth: adverse pregnancy outcomes and their association with maternal periodontitis. J Periodontol. Dec 2007;78(12):2266-76. [Medline].

21. Aly H, Alhabashi G, Hammad TA, Owusu-Ansah S, Bathgate S, Mohamed M. ABO phenotype and other risk factors associated with chorioamnionitis. J Pediatr. Jul 2008;153(1):16-8. [Medline].

22. Kabiru W, Raynor BD. Obstetric outcomes associated with increase in BMI category during pregnancy. Am J Obstet Gynecol. Sep 2004;191(3):928-32. [Medline].

23. Raatikainen K, Heiskanen N, Heinonen S. Transition from overweight to obesity worsens pregnancy outcome in a BMI-dependent manner. Obesity (Silver Spring). Jan 2006;14(1):165-71. [Medline].

24. Hassan S, Romero R, Hendler I, et al. A sonographic short cervix as the only clinical manifestation of intra-amniotic infection. J Perinat Med. 2006;34(1):13-9. [Medline].

25. Lee SE, Romero R, Park CW, Jun JK, Yoon BH. The frequency and significance of intraamniotic inflammation in patients with cervical insufficiency. Am J Obstet Gynecol. Jun 2008;198(6):633.e1-8. [Medline].

26. [Best Evidence] Heinemann J, Gillen G, Sanchez-Ramos L, Kaunitz AM. Do mechanical methods of cervical ripening increase infectious morbidity? A systematic review. Am J Obstet Gynecol. Aug 2008;199(2):177-87; discussion 187-8. [Medline].

27. Verma RP, Kaplan C, Southerton K, Niwas R, Verma R, Fang H. Placental histopathology in the extremely low birth weight infants. Fetal Pediatr Pathol. Aug 2008;27(2):53-61. [Medline].

28. Newton ER. Preterm labor, preterm premature rupture of membranes, and chorioamnionitis. Clin Perinatol. Sep 2005;32(3):571-600. [Medline].

29. Obi SN, Ozumba BC. Pre-term premature rupture of fetal membranes: the dilemma of management in a developing nation. J Obstet Gynaecol. Jan 2007;27(1):37-40. [Medline].

30. Naeye RL, Tafari N, Judge D, Gilmour D, Marboe C. Amniotic fluid infections in an African city. J Pediatr. Jun 1977;90(6):965-70. [Medline].

31. Appelbaum PC, Ross SM, Dhupelia I, Naeye RL. The effect of diet supplementation and addition of zinc in vitro on the growth-supporting property of amniotic fluid in African women. Am J Obstet Gynecol. Sep 1 1979;135(1):82-4. [Medline].

32. Katona P, Katona-Apte J. The interaction between nutrition and infection. Clin Infect Dis. May 15 2008;46(10):1582-8. [Medline].

33. Goldenberg RL, Andrews WW, Faye-Petersen OM, Cliver SP, Goepfert AR, Hauth JC. The Alabama preterm birth study: corticosteroids and neonatal outcomes in 23- to 32-week newborns with various markers of intrauterine infection. Am J Obstet Gynecol. Oct 2006;195(4):1020-4. [Medline].

34. Neufeld MD, Frigon C, Graham AS, Mueller BA. Maternal infection and risk of cerebral palsy in term and preterm infants. J Perinatol. Feb 2005;25(2):108-13. [Medline].

35. Versland LB, Sommerfelt K, Elgen I. Maternal signs of chorioamnionitis: persistent cognitive impairment in low-birthweight children. Acta Paediatr. Feb 2006;95(2):231-5. [Medline].

36. Bashiri A, Burstein E, Mazor M. Cerebral palsy and fetal inflammatory response syndrome: a review. J Perinat Med. 2006;34(1):5-12. [Medline].

37. Hagberg H, Mallard C, Jacobsson B. Role of cytokines in preterm labour and brain injury. BJOG. Mar 2005;112 Suppl 1:16-8. [Medline].

38. Redline R, Minich N, Taylor H, Hack M. Placental lesions as predictors of cerebral palsy and abnormal neurocognitive function at school age in extremely low birth weight infants (<1 Kg). Pediatr Dev Pathol. Mar 22 2007;1. [Medline].

39. Viscardi RM, Muhumuza CK, Rodriguez A, et al. Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurologic outcomes in preterm infants. Pediatr Res. Jun 2004;55(6):1009-17. [Medline].

40. Schelonka RL, Waites KB. Ureaplasma infection and neonatal lung disease. Semin Perinatol. Feb 2007;31(1):2-9. [Medline].

41. Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr Opin Infect Dis. Jun 2006;19(3):290-7. [Medline].

42. Ragouilliaux CJ, Keeney SE, Hawkins HK, Rowen JL. Maternal factors in extremely low birth weight infants who develop spontaneous intestinal perforation. Pediatrics. Dec 2007;120(6):e1458-64. [Medline].

43. Wu YW, Escobar GJ, Grether JK, Croen LA, Greene JD, Newman TB. Chorioamnionitis and cerebral palsy in term and near-term infants. JAMA. Nov 26 2003;290(20):2677-84. [Medline].

44. Dulay AT, Buhimschi IA, Zhao G, et al. Nucleated red blood cells are a direct response to mediators of inflammation in newborns with early-onset neonatal sepsis. Am J Obstet Gynecol. Apr 2008;198(4):426.e1-9. [Medline].

45. Redline RW. Elevated circulating fetal nucleated red blood cells and placental pathology in term infants who develop cerebral palsy. Hum Pathol. Sep 2008;39(9):1378-84. [Medline].

46. Holzman C, Lin X, Senagore P, Chung H. Histologic chorioamnionitis and preterm delivery. Am J Epidemiol. Oct 1 2007;166(7):786-94. [Medline].

47. Berenson AB, Wiemann CM, Wilkinson GS. Perinatal morbidity associated with violence experienced by pregnant women. Am J Obstet Gynecol. Jun 1994;170(6):1760-6; discussion 1766-9. [Medline].

48. Turner BJ, McKee LJ, Silverman NS. Prenatal care and birth outcomes of a cohort of HIV-infected women. J Acquir Immune Defic Syndr Hum Retrovirol. Jul 1996;12(3):259-67. [Medline].

49. Scholl TO. High third-trimester ferritin concentration: associations with very preterm delivery, infection, and maternal nutritional status. Obstet Gynecol. Aug 1998;92(2):161-6. [Medline].

50. Romero R, Chaiworapongsa T, Espinoza J. Micronutrients and intrauterine infection, preterm birth and the fetal inflammatory response syndrome. J Nutr. May 2003;133(5 Suppl 2):1668S-1673S. [Medline].

51. St Geme JW, Murray DL, Carter J. Perinatal bacterial infection after prolonged rupture of amniotic membranes: an analysis of risk and management. J Pediatr. Apr 1984;104(4):608-13. [Medline].

52. Rickert VI, Wiemann CM, Hankins GD, McKee JM, Berenson AB. Prevalence and risk factors of chorioamnionitis among adolescents. Obstet Gynecol. Aug 1998;92(2):254-7. [Medline].

53. Jolly MC, Sebire N, Harris J, Robinson S, Regan L. Obstetric risks of pregnancy in women less than 18 years old. Obstet Gynecol. Dec 2000;96(6):962-6. [Medline].

54. O'Brien RF. Bacterial vaginosis: many questions--any answers?. Curr Opin Pediatr. Aug 2005;17(4):473-9. [Medline].

55. Raatikainen K, Heiskanen N, Verkasalo PK, Heinonen S. Good outcome of teenage pregnancies in high-quality maternity care. Eur J Public Health. Apr 2006;16(2):157-61. [Medline].

56. Snyder M, Crawford P, Jamieson B, Neher JO. Clinical inquiries. What treatment approach to intrapartum maternal fever has the best fetal outcomes?. J Fam Pract. May 2007;56(5):401-2. [Medline].

57. Driscoll SG. Chorioamnionitis: perinatal morbidity and mortality. Pediatr Infect Dis. Nov-Dec 1986;5(6 Suppl):S273-5. [Medline].

58. [Best Evidence] Tran SH, Cheng YW, Kaimal AJ, Caughey AB. Length of rupture of membranes in the setting of premature rupture of membranes at term and infectious maternal morbidity. Am J Obstet Gynecol. Jun 2008;198(6):700.e1-5. [Medline].

59. Nath CA, Ananth CV, Smulian JC, Shen-Schwarz S, Kaminsky L. Histologic evidence of inflammation and risk of placental abruption. Am J Obstet Gynecol. Sep 2007;197(3):319.e1-6. [Medline].

60. Miller JM Jr, Kho MS, Brown HL, Gabert HA. Clinical chorioamnionitis is not predicted by an ultrasonic biophysical profile in patients with premature rupture of membranes. Obstet Gynecol. Dec 1990;76(6):1051-4. [Medline].

61. Vintzileos AM, Campbell WA, Nochimson DJ. Fetal breathing as a predictor of infection in premature rupture of the membranes. Obstet Gynecol. Jun 1986;67(6):813-7. [Medline].

62. Vintzileos AM, Campbell WA, Nochimson DJ. The fetal biophysical profile in patients with premature rupture of the membranes--an early predictor of fetal infection. Am J Obstet Gynecol. Jul 1 1985;152(5):510-6. [Medline].

63. Kusanovic JP, Espinoza J, Romero R, et al. Clinical significance of the presence of amniotic fluid 'sludge' in asymptomatic patients at high risk for spontaneous preterm delivery. Ultrasound Obstet Gynecol. Oct 2007;30(5):706-14. [Medline].

64. Aina-Mumuney AJ, Althaus JE, Henderson JL, Blakemore MC, Johnson EA, Graham EM. Intrapartum electronic fetal monitoring and the identification of systemic fetal inflammation. J Reprod Med. Sep 2007;52(9):762-8. [Medline].

65. Lieberman E, Lang JM, Frigoletto F Jr. Epidural analgesia, intrapartum fever, and neonatal sepsis evaluation. Pediatrics. Mar 1997;99(3):415-9. [Medline].

66. Lieberman E, Lang J, Richardson DK. Intrapartum maternal fever and neonatal outcome. Pediatrics. Jan 2000;105(1 Pt 1):8-13. [Medline].

67. Vallejo MC, Kaul B, Adler LJ. Chorioamnionitis, not epidural analgesia, is associated with maternal fever during labour. Can J Anaesth. Dec 2001;48(11):1122-6. [Medline].

68. Leighton BL, Halpern SH. Epidural analgesia: effects on labor progress and maternal and neonatal outcome. Semin Perinatol. Apr 2002;26(2):122-35. [Medline].

69. Goetzl L, Evans T, Rivers J. Elevated maternal and fetal serum interleukin-6 levels are associated with epidural fever. Am J Obstet Gynecol. Oct 2002;187(4):834-8. [Medline].

70. Alexander JM. Epidural analgesia for labor pain and its relationship to fever. Clin Perinatol. Sep 2005;32(3):777-87. [Medline].

71. Otsuki K, Yoda A, Saito H. Amniotic fluid lactoferrin in intrauterine infection. Placenta. Mar-Apr 1999;20(2-3):175-9. [Medline].

72. Hein M, Valore EV, Helmig RB. Antimicrobial factors in the cervical mucus plug. Am J Obstet Gynecol. Jul 2002;187(1):137-44. [Medline].

73. King AE, Critchley HO, Kelly RW. Innate immune defences in the human endometrium. Reprod Biol Endocrinol. Nov 28 2003;1:116. [Medline].

74. Akinbi HT, Narendran V, Pass AK. Host defense proteins in vernix caseosa and amniotic fluid. Am J Obstet Gynecol. Dec 2004;191(6):2090-6. [Medline].

75. Soto E, Espinoza J, Nien JK, et al. Human beta-defensin-2: a natural antimicrobial peptide present in amniotic fluid participates in the host response to microbial invasion of the amniotic cavity. J Matern Fetal Neonatal Med. Jan 2007;20(1):15-22. [Medline].

76. King AE, Kelly RW, Sallenave JM, Bocking AD, Challis JR. Innate immune defences in the human uterus during pregnancy. Placenta. Nov-Dec 2007;28(11-12):1099-106. [Medline].

77. Gomez R, Romero R, Nien JK. A short cervix in women with preterm labor and intact membranes: a risk factor for microbial invasion of the amniotic cavity. Am J Obstet Gynecol. Mar 2005;192(3):678-89. [Medline].

78. Wilks M, Wiggins R, Whiley A. Identification and H(2)O(2) production of vaginal lactobacilli from pregnant women at high risk of preterm birth and relation with outcome. J Clin Microbiol. Feb 2004;42(2):713-7. [Medline].

79. Balu RB, Savitz DA, Ananth CV. Bacterial vaginosis, vaginal fluid neutrophil defensins, and preterm birth. Obstet Gynecol. May 2003;101(5 Pt 1):862-8. [Medline].

80. Simoes JA, Aroutcheva A, Heimler I. Bacteriocin susceptibility of Gardnerella vaginalis and its relationship to biotype, genotype, and metronidazole susceptibility. Am J Obstet Gynecol. Nov 2001;185(5):1186-90. [Medline].

81. Reid G, Burton J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect. Mar 2002;4(3):319-24. [Medline].

82. McGaw T. Periodontal disease and preterm delivery of low-birth-weight infants. J Can Dent Assoc. Mar 2002;68(3):165-9. [Medline].

83. Urban E, Radnai M, Novak T. Distribution of anaerobic bacteria among pregnant periodontitis patients who experience preterm delivery. Anaerobe. Feb 2006;12(1):52-7. [Medline].

84. Matorras R, Garcia Perea A, Omenaca F, Usandizaga JA, Nieto A, Herruzo R. Group B streptococcus and premature rupture of membranes and preterm delivery. Gynecol Obstet Invest. 1989;27(1):14-8. [Medline].

85. Sanchez PJ, Regan JA. Vertical transmission of Ureaplasma urealyticum from mothers to preterm infants. Pediatr Infect Dis J. Jun 1990;9(6):398-401. [Medline].

86. Spiegel CA. Bacterial vaginosis. Clin Microbiol Rev. Oct 1991;4(4):485-502. [Medline].

87. Donder GG, Vereecken A, Bosmans E. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG. Jan 2002;109(1):34-43. [Medline].

88. Dixon NG, Ebright D, Defrancesco MA. Orogenital contact: a cause of chorioamnionitis?. Obstet Gynecol. Oct 1994;84(4 Pt 2):654-5. [Medline].

89. Hansen LM, Dorsey TA, Batzer FA. Capnocytophaga chorioamnionitis after oral sex. Obstet Gynecol. Oct 1996;88(4 Pt 2):731. [Medline].

90. Naeye RL, Ross S. Coitus and chorioamnionitis: a prospective study. Early Hum Dev. Jan 1982;6(1):91-7. [Medline].

91. [Best Evidence] Yost NP, Owen J, Berghella V. Effect of coitus on recurrent preterm birth. Obstet Gynecol. Apr 2006;107(4):793-7. [Medline].

92. Figueroa R, Garry D, Elimian A. Evaluation of amniotic fluid cytokines in preterm labor and intact membranes. J Matern Fetal Neonatal Med. Oct 2005;18(4):241-7. [Medline].

93. Volante E, Moretti S, Pisani F. Early diagnosis of bacterial infection in the neonate. J Matern Fetal Neonatal Med. Nov 2004;16 Suppl 2:13-6. [Medline].

94. Kayem G, Goffinet F, Batteux F. Detection of interleukin-6 in vaginal secretions of women with preterm premature rupture of membranes and its association with neonatal infection: a rapid immunochromatographic test. Am J Obstet Gynecol. Jan 2005;192(1):140-5. [Medline].

95. Straka M, Dela Cruz W, Blackmon C. Rapid detection of group B streptococcus and Escherichia coli in amniotic fluid using real-time fluorescent PCR. Infect Dis Obstet Gynecol. Sep-Dec 2004;12(3-4):109-14. [Medline].

96. Akers A, Jarzembowski JA, Johnson CT, Lieberman RW, Dalton VK. Examining the relationship between positive mid-gestational fetal fibronectin assays and histological evidence of acute placental inflammation. J Perinat Med. 2007;35(1):36-42. [Medline].

97. Buhimschi CS, Bhandari V, Hamar BD, et al. Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal sepsis. PLoS Med. Jan 2007;4(1):e18. [Medline].

98. Perinatal group B streptococcal disease after universal screening recommendations--United States, 2003-2005. MMWR Morb Mortal Wkly Rep. Jul 20 2007;56(28):701-5. [Medline].

99. Elvedi-Gasparovic V, Peter B. Maternal group B streptococcus infection, neonatal outcome and the role of preventive strategies. Coll Antropol. Mar 2008;32(1):147-51. [Medline].

100. Benitz WE, Gould JB, Druzin ML. Preventing early-onset group B streptococcal sepsis: strategy development using decision analysis. Pediatrics. Jun 1999;103(6):e76. [Medline].

101. Akker-van Marle ME, Rijnders ME, Dommelen P, et al. Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal disease. BJOG. Jun 2005;112(6):820-6. [Medline].

102. Shim SS, Romero R, Jun JK. C-reactive protein concentration in vaginal fluid as a marker for intra-amniotic inflammation/infection in preterm premature rupture of membranes. J Matern Fetal Neonatal Med. Dec 2005;18(6):417-22. [Medline].

103. Wiwanitkit V. Maternal C-reactive protein for detection of chorioamnionitis: an appraisal. Infect Dis Obstet Gynecol. Sep 2005;13(3):179-81. [Medline].

104. Visser VE, Hall RT. Urine culture in the evaluation of suspected neonatal sepsis. J Pediatr. Apr 1979;94(4):635-8. [Medline].

105. Sherman MP, Chance KH, Goetzman BW. Gram's stains of tracheal secretions predict neonatal bacteremia. Am J Dis Child. Sep 1984;138(9):848-50. [Medline].

106. Wiswell TE, Baumgart S, Gannon CM. No lumbar puncture in the evaluation for early neonatal sepsis: will meningitis be missed?. Pediatrics. Jun 1995;95(6):803-6. [Medline].

107. Sherman MP, Goetzman BW, Ahlfors CE. Tracheal asiration and its clinical correlates in the diagnosis of congenital pneumonia. Pediatrics. Feb 1980;65(2):258-63. [Medline].

108. Manroe BL, Rosenfeld CR, Weinberg AG. The differential leukocyte count in the assessment and outcome of early-onset neonatal group B streptococcal disease. J Pediatr. Oct 1977;91(4):632-7. [Medline].

109. Manroe BL, Weinberg AG, Rosenfeld CR. The neonatal blood count in health and disease. I. Reference values for neutrophilic cells. J Pediatr. Jul 1979;95(1):89-98. [Medline].

110. Cornbleet PJ. Clinical utility of the band count. Clin Lab Med. Mar 2002;22(1):101-36. [Medline].

111. Christensen RD, Henry E, Wiedmeier SE, Stoddard RA, Lambert DK. Low blood neutrophil concentrations among extremely low birth weight neonates: data from a multihospital health-care system. J Perinatol. Nov 2006;26(11):682-7. [Medline].

112. Christensen RD. Morphology and concentration of circulating neutrophils in neonates with bacterial sepsis. Pediatr Infect Dis J. May 1987;6(5):429-30. [Medline].

113. Christensen RD, Rothstein G, Anstall HB, Bybee B. Granulocyte transfusions in neonates with bacterial infection, neutropenia, and depletion of mature marrow neutrophils. Pediatrics. Jul 1982;70(1):1-6. [Medline].

114. Benitz WE, Han MY, Madan A. Serial serum C-reactive protein levels in the diagnosis of neonatal infection. Pediatrics. Oct 1998;102(4):e41. [Medline].

115. Joram N, Boscher C, Denizot S. Umbilical cord blood procalcitonin and C reactive protein concentrations as markers for early diagnosis of very early onset neonatal infection. Arch Dis Child Fetal Neonatal Ed. Jan 2006;91(1):F65-6. [Medline].

116. Ng PC, Li G, Chui KM, et al. Neutrophil CD64 is a sensitive diagnostic marker for early-onset neonatal infection. Pediatr Res. Nov 2004;56(5):796-803. [Medline].

117. Ng PC, Li G, Chui KM, et al. Quantitative measurement of monocyte HLA-DR expression in the identification of early-onset neonatal infection. Biol Neonate. 2006;89(2):75-81. [Medline].

118. Mishra UK, Jacobs SE, Doyle LW, Garland SM. Newer approaches to the diagnosis of early onset neonatal sepsis. Arch Dis Child Fetal Neonatal Ed. May 2006;91(3):F208-12. [Medline].

119. Brozanski BS, Jones JG, Krohn MJ, Jordan JA. Use of polymerase chain reaction as a diagnostic tool for neonatal sepsis can result in a decrease in use of antibiotics and total neonatal intensive care unit length of stay. J Perinatol. Nov 2006;26(11):688-92. [Medline].

120. Makhoul IR, Sprecher H, Smolkin T, Sawaid R, Ben-David S, Sujov P, et al. Approach to term neonates born after maternal intrapartum fever and unknown maternal group B Streptococcus status: value of serum C-reactive protein and 16S rRNA gene PCR amplification. Pediatr Infect Dis J. Nov 2007;26(11):1064-6. [Medline].

121. Ohlin A, Backman A, Bjorkqvist M, Molling P, Jurstrand M, Schollin J. Real-time PCR of the 16S-rRNA gene in the diagnosis of neonatal bacteraemia. Acta Paediatr. Oct 2008;97(10):1376-80. [Medline].

122. Sherer DM, Spong CY, Salafia CM. Fetal breathing movements within 24 hours of delivery in prematurity are related to histologic and clinical evidence of amnionitis. Am J Perinatol. Jul 1997;14(6):337-40. [Medline].

123. Ghidini A, Salafia CM, Kirn V. Biophysical profile in predicting acute ascending infection in preterm rupture of membranes before 32 weeks. Obstet Gynecol. Aug 2000;96(2):201-6. [Medline].

124. Rizzo G, Capponi A, Vlachopoulou A, Angelini E, Grassi C, Romanini C. Ultrasonographic assessment of the uterine cervix and interleukin-8 concentrations in cervical secretions predict intrauterine infection in patients with preterm labor and intact membranes. Ultrasound Obstet Gynecol. Aug 1998;12(2):86-92. [Medline].

125. Heller DS, Rimpel LH, Skurnick JH. Does histologic chorioamnionitis correspond to clinical chorioamnionitis?. J Reprod Med. Jan 2008;53(1):25-8. [Medline].

126. Redline RW, Faye-Petersen O, Heller D, Qureshi F, Savell V, Vogler C. Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol. Sep-Oct 2003;6(5):435-48. [Medline].

127. Lim L, Rozycki HJ. Postnatal SNAP-II scores in neonatal intensive care unit patients: relationship to sepsis, necrotizing enterocolitis, and death. J Matern Fetal Neonatal Med. Jun 2008;21(6):415-9. [Medline].

128. Winn HN. Group B streptococcus infection in pregnancy. Clin Perinatol. Sep 2007;34(3):387-92. [Medline].

129. Schrag SJ, Zell ER, Lynfield R. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med. Jul 25 2002;347(4):233-9. [Medline].

130. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep. Aug 16 2002;51:1-22. [Medline]. [Full Text].

131. Apgar BS, Greenberg G, Yen G. Prevention of group B streptococcal disease in the newborn. Am Fam Physician. Mar 1 2005;71(5):903-10. [Medline].

132. Amstey MS, Gibbs RS. Is penicillin G a better choice than ampicillin for prophylaxis of neonatal group B streptococcal infections?. Obstet Gynecol. Dec 1994;84(6):1058-9. [Medline].

133. Alarcon A, Pena P, Salas S, et al. Neonatal early onset Escherichia coli sepsis: trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial prophylaxis. Pediatr Infect Dis J. Apr 2004;23(4):295-9. [Medline].

134. Gibbs RS, Schrag S, Schuchat A. Perinatal infections due to group B streptococci. Obstet Gynecol. Nov 2004;104(5 Pt 1):1062-76. [Medline].

135. Schelonka RL, Infante AJ. Neonatal immunology. Semin Perinatol. Feb 1998;22(1):2-14. [Medline].

136. Suri M, Harrison L, Van de Ven C, Cairo MS. Immunotherapy in the prophylaxis and treatment of neonatal sepsis. Curr Opin Pediatr. Apr 2003;15(2):155-60. [Medline].

137. Shaw CK, Thapalial A, Shaw P, Malla K. Intravenous immunoglobulins and haematopoietic growth factors in the prevention and treatment of neonatal sepsis: ground reality or glorified myths?. Int J Clin Pract. Mar 2007;61(3):482-7. [Medline].

138. Boggess KA. Pathophysiology of preterm birth: emerging concepts of maternal infection. Clin Perinatol. Sep 2005;32(3):561-9. [Medline].

139. [Best Evidence] Shennan A, Crawshaw S, Briley A. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study. BJOG. Jan 2006;113(1):65-74. [Medline].

140. Borchardt SM, DeBusscher JH, Tallman PA, et al. Frequency of antimicrobial resistance among invasive and colonizing Group B streptococcal isolates. BMC Infect Dis. Mar 20 2006;6:57. [Medline].

141. Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA. May 7 2008;299(17):2056-65. [Medline].

142. Young TE, Mangum B. Antimicrobials. In: NEOFAX 2008. 21st Edition. Montvale, NJ: Thomson Reuters; 2008:1-79.

143. Speer CP. Pulmonary inflammation and bronchopulmonary dysplasia. J Perinatol. May 2006;26 Suppl 1:S57-62; discussion S63-4. [Medline].

144. Ryan RM, Ahmed Q, Lakshminrusimha S. Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia. Clin Rev Allergy Immunol. Apr 2008;34(2):174-90. [Medline].

145. Weinstein L. A multifacited approach to improve patient safety, prevent medical errors and resolve the professional liability crisis. Am J Obstet Gynecol. Apr 2006;194(4):1160-5; discussion 1165-7. [Medline].

146. Donn SM. Medical liability, risk management, and the quality of health care. Semin Fetal Neonatal Med. Feb 2005;10(1):3-9. [Medline].

147. Shwayder JM. Liability in high-risk obstetrics. Obstet Gynecol Clin North Am. Sep 2007;34(3):617-25, xiv. [Medline].

148. Bonadio WA. Medical-legal considerations related to symptom duration and patient outcome after bacterial meningitis. Am J Emerg Med. Jul 1997;15(4):420-3. [Medline].

149. Shalak LF, Laptook AR, Jafri HS. Clinical chorioamnionitis, elevated cytokines, and brain injury in term infants. Pediatrics. Oct 2002;110(4):673-80. [Medline].

150. Grether JK, Nelson KB, Walsh E. Intrauterine exposure to infection and risk of cerebral palsy in very preterm infants. Arch Pediatr Adolesc Med. Jan 2003;157(1):26-32. [Medline].

151. Graham EM, Holcroft CJ, Rai KK. Neonatal cerebral white matter injury in preterm infants is associated with culture positive infections and only rarely with metabolic acidosis. Am J Obstet Gynecol. Oct 2004;191(4):1305-10. [Medline].

152. Seubert DE, Huang WM, Wasserman-Hoff R. Medical legal issues in the prevention of prematurity. Clin Perinatol. Jun 2007;34(2):309-18, vii. [Medline].

153. Yancey MK, Zhang J, Schwarz J, Dietrich CS 3rd, Klebanoff M. Labor epidural analgesia and intrapartum maternal hyperthermia. Obstet Gynecol. Nov 2001;98(5 Pt 1):763-70. [Medline].

154. Mantha VR, Vallejo MC, Ramesh V, Phelps AL, Ramanathan S. The incidence of maternal fever during labor is less with intermittent than with continuous epidural analgesia: a randomized controlled trial. Int J Obstet Anesth. Apr 2008;17(2):123-9. [Medline].

155. Impey L, Greenwood C, MacQuillan K, Reynolds M, Sheil O. Fever in labour and neonatal encephalopathy: a prospective cohort study. BJOG. Jun 2001;108(6):594-7. [Medline].

156. Goldenberg RL, Andrews WW, Goepfert AR, et al. The Alabama Preterm Birth Study: umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants. Am J Obstet Gynecol. Jan 2008;198(1):43.e1-5. [Medline].

157. Andrews WW, Hauth JC, Cliver SP, Savage K, Goldenberg RL. Randomized clinical trial of extended spectrum antibiotic prophylaxis with coverage for Ureaplasma urealyticum to reduce post-cesarean delivery endometritis. Obstet Gynecol. Jun 2003;101(6):1183-9. [Medline].

158. Matlow A, Th'ng C, Kovach D, Quinn P, Dunn M, Wang E. Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents. Antimicrob Agents Chemother. May 1998;42(5):1290-2. [Medline].

159. ACOG Statement. ACOG practice bulletin. Premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. Number 1, June 1998. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. Oct 1998;63(1):75-84. [Medline].

160. Alanen A. Polymerase chain reaction in the detection of microbes in amniotic fluid. Ann Med. Jun 1998;30(3):288-95. [Medline].

161. Andrews WW, Cliver SP, Biasini F, et al. Early preterm birth: association between in utero exposure to acute inflammation and severe neurodevelopmental disability at 6 years of age. Am J Obstet Gynecol. Apr 2008;198(4):466.e1-466.e11. [Medline].

162. Badri MS, Zawaneh S, Cruz AC. Rectal colonization with group B streptococcus: relation to vaginal colonization of pregnant women. J Infect Dis. Feb 1977;135(2):308-12. [Medline].

163. Benitz WE, Gould JB, Druzin ML. Risk factors for early-onset group B streptococcal sepsis: estimation of odds ratios by critical literature review. Pediatrics. Jun 1999;103(6):e77. [Medline].

164. Berger C, Uehlinger J, Ghelfi D. Comparison of C-reactive protein and white blood cell count with differential in neonates at risk for septicemia. Eur J Pediatr. Feb 1995;154(2):138-44. [Medline].

165. Bint AJ, Hill D. Bacteriuria of pregnancy--an update on significance, diagnosis and management. J Antimicrob Chemother. May 1994;33 Suppl A:93-7. [Medline].

166. Boggess KA, Trevett TN, Madianos PN. Use of DNA hybridization to detect vaginal pathogens associated with bacterial vaginosis among asymptomatic pregnant women. Am J Obstet Gynecol. Sep 2005;193(3 Pt 1):752-6. [Medline].

167. Brocklehurst P. Infection and preterm delivery. BMJ. Feb 27 1999;318(7183):548-9. [Medline].

168. Carey JC, Klebanoff MA, Hauth JC. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. Feb 24 2000;342(8):534-40. [Medline].

169. Christensen RD, Rothstein G, Hill HR. Fatal early onset group B streptococcal sepsis with normal leukocyte counts. Pediatr Infect Dis. May-Jun 1985;4(3):242-5. [Medline].

170. Churgay CA, Smith MA, Blok B. Maternal fever during labor--what does it mean?. J Am Board Fam Pract. Jan-Feb 1994;7(1):14-24. [Medline].

171. Dashe JS, Rogers BB, McIntire DD. Epidural analgesia and intrapartum fever: placental findings. Obstet Gynecol. Mar 1999;93(3):341-4. [Medline].

172. Dobson SR, Isaacs D, Wilkinson AR. Reduced use of surface cultures for suspected neonatal sepsis and surveillance. Arch Dis Child. Jan 1992;67(1 Spec No):44-7. [Medline].

173. Dudley DJ. Immunoendocrinology of preterm labor: the link between corticotropin-releasing hormone and inflammation. Am J Obstet Gynecol. Jan 1999;180(1 Pt 3):S251-6. [Medline].

174. Espinoza J, Chaiworapongsa T, Romero R. Antimicrobial peptides in amniotic fluid: defensins, calprotectin and bacterial/permeability-increasing protein in patients with microbial invasion of the amniotic cavity, intra-amniotic inflammation, preterm labor and premature rupture of membranes. J Matern Fetal Neonatal Med. Jan 2003;13(1):2-21. [Medline].

175. Garcia-Prats JA, Cooper TR, Schneider VF. Rapid detection of microorganisms in blood cultures of newborn infants utilizing an automated blood culture system. Pediatrics. Mar 2000;105(3 Pt 1):523-7. [Medline].

176. Garite TJ, Freeman RK. Chorioamnionitis in the preterm gestation. Obstet Gynecol. May 1982;59(5):539-45. [Medline].

177. Gibbs RS, Davies JK, McDuffie RS Jr. Chronic intrauterine infection and inflammation in the preterm rabbit, despite antibiotic therapy. Am J Obstet Gynecol. Feb 2002;186(2):234-9. [Medline].

178. Gibbs RS, Duff P. Progress in pathogenesis and management of clinical intraamniotic infection. Am J Obstet Gynecol. May 1991;164(5 Pt 1):1317-26. [Medline].

179. Gilstrap LC 3d, Leveno KJ, Cox SM. Intrapartum treatment of acute chorioamnionitis: impact on neonatal sepsis. Am J Obstet Gynecol. Sep 1988;159(3):579-83. [Medline].

180. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med. May 18 2000;342(20):1500-7. [Medline].

181. Goldenberg RL, Mercer BM, Miodovnik M. Plasma ferritin, premature rupture of membranes, and pregnancy outcome. Am J Obstet Gynecol. Dec 1998;179(6 Pt 1):1599-604. [Medline].

182. [Best Evidence] Goldenberg RL, Mwatha A, Read JS. The HPTN 024 Study: the efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol. Mar 2006;194(3):650-61. [Medline].

183. Gomez R, Ghezzi F, Romero R. Premature labor and intra-amniotic infection. Clinical aspects and role of the cytokines in diagnosis and pathophysiology. Clin Perinatol. Jun 1995;22(2):281-342. [Medline].

184. Gonzalez-Bosquet E, Cerqueira MJ, Dominguez C. Amniotic fluid glucose and cytokines values in the early diagnosis of amniotic infection in patients with preterm labor and intact membranes. J Matern Fetal Med. Jul-Aug 1999;8(4):155-8. [Medline].

185. Hachey WE, Wiswell TE. Limitations in the usefulness of urine latex particle agglutination tests and hematologic measurements in diagnosing neonatal sepsis during the first week of life. J Perinatol. Sep 1992;12(3):240-5. [Medline].

186. Hauth JC, Gilstrap LC 3d, Hankins GD. Term maternal and neonatal complications of acute chorioamnionitis. Obstet Gynecol. Jul 1985;66(1):59-62. [Medline].

187. Heighton BL, Halpren SH. The effects of epidural analgesia on labor, maternal, and neonatal outcomes: a systematic review. Am J Obstet Gynecol. 2002;186(5 Suppl Nature):S69-77.

188. Hemming VG, McCloskey DW, Hill HR. Pneumonia in the neonate associated with group B streptococcal septicemia. Am J Dis Child. Nov 1976;130(11):1231-3. [Medline].

189. Hillier SL, Martius J, Krohn M. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med. Oct 13 1988;319(15):972-8. [Medline].

190. Hussey MJ, Levy ES, Pombar X. Evaluating rapid diagnostic tests of intra-amniotic infection: Gram stain, amniotic fluid glucose level, and amniotic fluid to serum glucose level ratio. Am J Obstet Gynecol. Sep 1998;179(3 Pt 1):650-6. [Medline].

191. Ismail MA, Zinaman MJ, Lowensohn RI. The significance of C-reactive protein levels in women with premature rupture of membranes. Am J Obstet Gynecol. Feb 15 1985;151(4):541-4. [Medline].

192. Johnson CE, Whitwell JK, Pethe K. Term newborns who are at risk for sepsis: are lumbar punctures necessary?. Pediatrics. Apr 1997;99(4):e10. [Medline].

193. Joseph TA, Pyati SP, Jacobs N. Neonatal early-onset Escherichia coli disease. The effect of intrapartum ampicillin. Arch Pediatr Adolesc Med. Jan 1998;152(1):35-40. [Medline].

194. Kaftan H, Kinney JS. Early onset neonatal bacterial infections. Semin Perinatol. Feb 1998;22(1):15-24. [Medline].

195. Kurlat I, Stoll BJ, McGowan JE Jr. Time to positivity for detection of bacteremia in neonates. J Clin Microbiol. May 1989;27(5):1068-71. [Medline].

196. Maeda K, Matsuzaki N, Fuke S. Value of the maternal interleukin 6 level for determination of histologic chorioamnionitis in preterm delivery. Gynecol Obstet Invest. 1997;43(4):225-31. [Medline].

197. Mangurten HH, Angst DB, See C, Boyle D, Beckman S. Professional liability in a neonatal intensive care unit: a review of 20 years' experience. J Perinatol. Jun 2000;20(4):244-8. [Medline].

198. Mercer BM, Lewis R. Preterm labor and preterm premature rupture of the membranes. Diagnosis and management. Infect Dis Clin North Am. Mar 1997;11(1):177-201. [Medline].

199. Miura E, Procianoy RS, Bittar C. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics. Jan 2001;107(1):30-5. [Medline].

200. Moore SE, Cole TJ, Collinson AC. Prenatal or early postnatal events predict infectious deaths in young adulthood in rural Africa. Int J Epidemiol. Dec 1999;28(6):1088-95. [Medline].

201. Murtha AP, Greig PC, Jimmerson CE. Maternal serum interleukin-6 concentrations in patients with preterm premature rupture of membranes and evidence of infection. Am J Obstet Gynecol. Oct 1996;175(4 Pt 1):966-9. [Medline].

202. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev. 2004;CD001239. [Medline].

203. Philip J, Alexander JM, Sharma SK. Epidural analgesia during labor and maternal fever. Anesthesiology. May 1999;90(5):1271-5. [Medline].

204. Pourcyrous M, Bada HS, Korones SB. Significance of serial C-reactive protein responses in neonatal infection and other disorders. Pediatrics. Sep 1993;92(3):431-5. [Medline].

205. Puopolo KM. Bacterial and fungal infections. In: Cloherty JP, Eichenwald EC, Stark AR, eds. Manual of Neonatal Care. 5^th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:287-313.

206. Romem Y, Artal R. C-reactive protein as a predictor for chorioamnionitis in cases of premature rupture of the membranes. Am J Obstet Gynecol. Nov 1 1984;150(5 Pt 1):546-50. [Medline].

207. Sanghvi KP, Tudehope DI. Neonatal bacterial sepsis in a neonatal intensive care unit: a 5 year analysis. J Paediatr Child Health. Aug 1996;32(4):333-8. [Medline].

208. Schmutz N, Henry E, Jopling J, Christensen RD. Expected ranges for blood neutrophil concentrations of neonates: the Manroe and Mouzinho charts revisited. J Perinatol. Apr 2008;28(4):275-81. [Medline].

209. Schuchat A, Zywicki SS, Dinsmoor MJ. Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study. Pediatrics. Jan 2000;105(1 Pt 1):21-6. [Medline].

210. Seaward PG, Hannah ME, Myhr TL. International multicenter term PROM study: evaluation of predictors of neonatal infection in infants born to patients with premature rupture of membranes at term. Premature Rupture of the Membranes. Am J Obstet Gynecol. Sep 1998;179(3 Pt 1):635-9. [Medline].

211. Seo K, McGregor JA, French JI. Preterm birth is associated with increased risk of maternal and neonatal infection. Obstet Gynecol. Jan 1992;79(1):75-80. [Medline].

212. Sherman MP. Macrophage function in bacterial and fungal infections of newborns. In: Lipscomb MF, Russell SW, eds. Lung macrophages and dendritic cells. Lung Biology in Health and Disease Series. Vol 102. New York, NY:. Marcel Dekker;1997:409-436.

213. Smulian JC, Shen-Schwarz S, Vintzileos AM. Clinical chorioamnionitis and histologic placental inflammation. Obstet Gynecol. Dec 1999;94(6):1000-5. [Medline].

214. Smulian JC, Vintzileos AM, Lai YL. Maternal chorioamnionitis and umbilical vein interleukin-6 levels for identifying early neonatal sepsis. J Matern Fetal Med. May-Jun 1999;8(3):88-94. [Medline].

215. Sreenan C, Osiovich H. Myeloid colony-stimulating factors: use in the newborn. Arch Pediatr Adolesc Med. Sep 1999;153(9):984-8. [Medline].

216. Stoll BJ, Hansen N, Fanaroff AA. Changes in pathogens causing early-onset sepsis in very-low-birth- weight infants. N Engl J Med. Jul 25 2002;347(4):240-7. [Medline].

217. Stoll BJ, Holman RC, Schuchat A. Decline in sepsis-associated neonatal and infant deaths in the United States, 1979 through 1994. Pediatrics. Aug 1998;102(2):e18. [Medline].

218. Teichmann AT, Arendt P, Speer CP. Premature rupture of the membranes and amniotic infections--the significance of laboratory tests. Eur J Obstet Gynecol Reprod Biol. Mar 1990;34(3):217-22. [Medline].

219. Terrone DA, Rinehart BK, Einstein MH. Neonatal sepsis and death caused by resistant Escherichia coli: possible consequences of extended maternal ampicillin administration. Am J Obstet Gynecol. Jun 1999;180(6 Pt 1):1345-8. [Medline].

220. Towers CV, Carr MH, Padilla G. Potential consequences of widespread antepartal use of ampicillin. Am J Obstet Gynecol. Oct 1998;179(4):879-83. [Medline].

221. Vollman JH, Smith WL, Ballard ET. Early onset group B streptococcal disease: clinical, roentgenographic, and pathologic features. J Pediatr. Aug 1976;89(2):199-203. [Medline].

222. Wolach B. Neonatal sepsis: pathogenesis and supportive therapy. Semin Perinatol. Feb 1997;21(1):28-38. [Medline].

223. Yoon BH, Jun JK, Romero R. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol. Jul 1997;177(1):19-26. [Medline].

224. Yoon BH, Romero R, Lim JH. The clinical significance of detecting Ureaplasma urealyticum by the polymerase chain reaction in the amniotic fluid of patients with preterm labor. Am J Obstet Gynecol. Oct 2003;189(4):919-24. [Medline].

225. Yoon BH, Romero R, Shim JY. C-reactive protein in umbilical cord blood: a simple and widely available clinical method to assess the risk of amniotic fluid infection and funisitis. J Matern Fetal Neonatal Med. Aug 2003;14(2):85-90. [Medline].

226. Yoon BH, Yang SH, Jun JK. Maternal blood C-reactive protein, white blood cell count, and temperature in preterm labor: a comparison with amniotic fluid white blood cell count. Obstet Gynecol. Feb 1996;87(2):231-7. [Medline].

Keywords

maternal chorioamnionitis, acute chorioamnionitis, early-onset neonatal sepsis, early onset neonatal sepsis, early onset sepsis, maternal and fetal effects of amniotic fluid infection, pregnancy and fetal infection with bacteria, preterm labor, premature rupture of membranes, epidural anesthesia, intrapartum fever, abnormal bacterial colonization of the urogenital tract, ascending amniotic fluid infection, asymptomatic chorioamnionitis, symptomatic chorioamnionitis, placental infection, funisitis, bacteremia, pneumonia, Escherichia coli, methicillin-resistant Staphylococcus aureus, urinary tract infection, UTI, bacterial vaginosis, alcoholism, prolonged rupture of membranes, maternal anemia, obesity, cerebral palsy, CP, periventricular leukomalacia, Ureaplasma, Mycoplasma, necrotizing enterocolitis, maternal leukocytosis, hypotension, vaginitis

Contributor Information and Disclosures

Author

Michael P Sherman, MD, Professor, Department of Pediatrics, Southern Illinois University School of Medicine; Coordinator, Pediatric Residency Education in Neonatal Intensive Care, St John's Children's Hospital; Professor Emeritus, Department of Pediatrics, University of California, Davis School of Medicine
Michael P Sherman, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, European Society for Paediatric Research, Perinatal Research Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Coauthor(s)

Katsufumi Otsuki, MD, PhD, Associate Professor, Department of Obstetrics and Gynecology, Showa University School of Medicine, Tokyo, Japan
Disclosure: Nothing to disclose.

Medical Editor

Ted Rosenkrantz, MD, Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine
Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Arun K Pramanik, MD, MBBS, Professor of Pediatrics, Director of Neonatal Fellowship, Louisiana State University Health Sciences Center
Arun K Pramanik, MD, MBBS is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, National Perinatal Association, and Southern Society for Pediatric Research
Disclosure: Nothing to disclose.

CME Editor

Carol L Wagner, MD, Professor of Pediatrics, Medical University of South Carolina
Carol L Wagner, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American Medical Women's Association, American Public Health Association, American Society for Bone and Mineral Research, American Society for Clinical Nutrition, Massachusetts Medical Society, National Perinatal Association, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD, Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine
Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Readers of this article are also encouraged to read chapters with a similar name in textbooks of Maternal and Fetal Medicine. Chapters on neonatal sepsis in textbooks of neonatal and perinatal medicine (ie, neonatology) enhance knowledge regarding recognition and management of early onset newborn infections. 

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)